# Chapter 101: Cannabis Intoxication

## The Biological and Neurological Basis of Cannabis Intoxication

### Introduction

Cannabis is the most widely used illicit psychoactive substance globally, with a landscape of use patterns ranging from experimental to dependent (Karila et al., 2014; Copeland et al., 2014). The state of cannabis intoxication, often sought for its recreational effects, represents a complex neuropsychiatric phenomenon rooted in the interaction between its primary psychoactive constituent, delta-9-tetrahydrocannabinol (THC), and the brain's endogenous cannabinoid system (Pytell & Rastegar, 2025; Hoch et al., 2024). From a biological perspective, intoxication is a transient condition following substance administration that results in disturbances in consciousness, cognition, perception, affect, or behavior (Sarkar et al., 2023; Tassinari et al., 1999). The subjective experience of cannabis intoxication typically includes relaxation, euphoria, and mild hallucinogenic effects (Pytell & Rastegar, 2025; Hollister, 1971), but can also manifest as adverse reactions such as anxiety, dysphoria, panic, and paranoia, particularly in naive users (Thomas, 1993; Hall, 2012).

Understanding the biological basis of these effects is critical, not only for contextualizing the user's experience but also for elucidating the mechanisms of cannabis use disorder (CUD) and the substance's impact on mental health (Daley & Douaihy, 2019). The psychoactive principles of cannabis, primarily THC, exert their influence by modifying the modulatory activity of the endocannabinoid system, a ubiquitous signaling network involved in brain development, plasticity, and homeostasis (Araos et al., 2014; Bulacia, 2016). This interaction triggers a cascade of neurochemical events that temporarily alter neural circuit function, giving rise to the cognitive, perceptual, and emotional changes characteristic of intoxication (Pearlson, 2020).

This chapter will provide a comprehensive overview of the biological and neurological mechanisms underlying cannabis intoxication. We will explore the neuropharmacology of cannabinoids, detailing their interaction with key neurotransmitter systems, including the dopaminergic, serotonergic, and GABAergic pathways. We will examine the specific brain regions and neural circuits implicated in the acute effects of cannabis, linking neuroanatomical findings to the phenomenological experience of intoxication. Furthermore, we will discuss the cellular and synaptic mechanisms, genetic predispositions, and neurodevelopmental factors that modulate an individual's response to cannabis. By synthesizing evidence from neuroimaging, preclinical models, and clinical studies, this chapter aims to construct a detailed, evidence-based account of how cannabis produces its profound, albeit transient, effects on the human brain and behavior.

### Neurobiological Systems

The diverse psychological and behavioral phenomena associated with cannabis intoxication are underpinned by the interaction of its psychoactive components with multiple neurobiological systems (Pearlson, 2020). The primary mediator of these effects is the endocannabinoid system (ECS), which in turn modulates a wide array of other critical neurotransmitter networks throughout the central nervous system (Araos et al., 2014).

#### The Endocannabinoid System

The cornerstone of cannabis's neuropharmacological action is the ECS, an endogenous signaling system comprising cannabinoid receptors, their endogenous ligands (endocannabinoids), and the enzymes responsible for their synthesis and degradation (Araos et al., 2014). The main psychoactive agent in cannabis, THC, exerts its effects by acting as a partial agonist at cannabinoid receptors, particularly the cannabinoid type 1 (CB1) receptor (Hoch et al., 2024; Pytell & Rastegar, 2025).

CB1 receptors are among the most abundant G-protein coupled receptors in the brain, with high densities in regions critical for cognition, memory, mood, and motor control (Araos et al., 2014; Dervaux, 2013). These regions include the hippocampus (memory), cerebellum (motor coordination), frontal cortex (executive functions), striatum and basal ganglia (motor control, reward), and amygdala (emotion processing) (Dervaux, 2013; Cermak, 2020). This specific distribution of CB1 receptors directly correlates with the well-documented effects of acute cannabis intoxication, such as impaired short-term memory, motor incoordination, altered judgment, and emotional lability (Hall, 2012; Ashton, 2018; Tassinari et al., 1999). Chronic stimulation of the ECS by exogenous cannabinoids like THC can induce neurobiological consequences, including dependence and alterations in cognitive processes (Araos et al., 2014). A second receptor, the cannabinoid type 2 (CB2) receptor, is found primarily in the periphery on immune cells, though its presence and function in the brain are areas of ongoing investigation (Rivera-Olmos & Parra-Bernal, 2016).

Endocannabinoids, such as anandamide and 2-arachidonoylglycerol, typically function as retrograde messengers (Araos et al., 2014). They are synthesized on demand in postsynaptic neurons and travel backward across the synapse to bind to presynaptic CB1 receptors, where they inhibit the release of other neurotransmitters like glutamate and GABA (Hertz et al., 2014). THC mimics this action but in a more widespread and sustained manner, leading to a global disruption of normative synaptic transmission and brain function (D'Souza, 2023).

#### Interaction with Major Neurotransmitter Systems

The modulatory role of the ECS means that THC's effects are not confined to a single pathway but rather produce a domino effect across multiple neurotransmitter systems (Rivera-Olmos & Parra-Bernal, 2016).

**Dopamine System:** The brain's reward circuitry, particularly the mesolimbic dopamine system, is critically involved in the reinforcing effects of cannabis and the development of CUD (Roques, 2000; Roberts & Koob, 1997). This system, which includes projections from the ventral tegmental area to the nucleus accumbens, is a common target for all drugs of abuse (Antonio & Alfredo, 2012; Scuvée‐Moreau, 2013). THC, by acting on CB1 receptors on GABAergic interneurons in the ventral tegmental area, disinhibits dopamine neurons, leading to increased dopamine release in the nucleus accumbens (Dodd, 2007; Roberts & Koob, 1997). This surge in dopamine is associated with the euphoria and pleasurable sensations reported during acute intoxication (Snyder, 2019; George & Koob, 2017). However, this same dopaminergic hyperactivity is also implicated in the psychotomimetic effects of cannabis, such as paranoia and, in vulnerable individuals, the precipitation of psychosis (Dodd, 2007; Hall & Degenhardt, 2010; Radhakrishnan et al., 2014). The dopamine hypothesis of schizophrenia posits that an excess of dopamine is linked to psychotic symptoms, and drugs that stimulate dopamine release, such as cannabis, amphetamines, and cocaine, can cause or exacerbate these symptoms (Dodd, 2007; Bell, 1973). This provides a plausible biological mechanism for the observed association between cannabis use and schizophrenia-like psychoses (Häfner, 2005; Jockers‐Scherübl, 2006).

**Serotonin System:** The serotonin (5-HT) system is integral to the regulation of mood, anxiety, sleep, and perception (Fiar et al., 2012). Hallucinogenic drugs such as LSD and psilocybin primarily exert their effects via the 5-HT system, particularly through agonist activity at 5-HT2A receptors (Pechnick et al., 2014; Torre et al., 2004). THC also modulates serotonergic neurotransmission, which may account for some of its effects on mood, its anxiolytic or anxiogenic properties, and its capacity to produce perceptual alterations (Schoedel & Harrison, 2012; Ashton et al., 2005). The interaction between the endocannabinoid and serotonergic systems may explain the anxiolytic effects some users seek, but also the panic attacks and anxiety that can occur, especially with high doses or in naive users (Thomas, 1993; Karila et al., 2014). Furthermore, this interaction is relevant to understanding the comorbidity between CUD and mood and anxiety disorders (Dervaux, 2018; Conway et al., 2007). The ability of cannabinoids to induce subjective effects like perceptual alterations, depersonalization, and derealization shares qualitative similarities with serotonergic hallucinogens, suggesting a potential overlap in mechanisms (Cole & Katz, 1964; Schoedel & Harrison, 2012).

**GABA and Glutamate Systems:** Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the brain, while glutamate is the primary excitatory one. The balance between these two systems is fundamental for neural homeostasis. CB1 receptors are densely expressed on both GABAergic and glutamatergic presynaptic terminals (Antonio & Alfredo, 2012). By inhibiting the release of these neurotransmitters, THC disrupts this delicate balance. Inhibition of GABA release can lead to disinhibition of downstream circuits (as seen in the dopamine system), while inhibition of glutamate release can result in suppressed neuronal activity (Becker & Redmond, 2002). This widespread disruption of excitatory and inhibitory signaling contributes significantly to the cognitive impairments seen during intoxication, including deficits in attention, learning, and memory (Araos et al., 2014; Oomen et al., 2018). Perturbations in GABAergic and glutamatergic transmission have been implicated in the pathophysiology of various conditions, including catatonia and alcohol withdrawal, highlighting the critical role of these systems in maintaining normal brain function (Yarlagadda et al., 2007; Zutshi et al., 2007). The sedative effects of cannabis can be partly attributed to the complex interplay of its effects on these opposing systems (Rastegar & Fingerhood, 2015).

### Genetic and Molecular Basis

The subjective and objective effects of cannabis intoxication are not uniform across all individuals, suggesting a significant contribution of genetic and molecular factors in modulating response to the drug (George & Koob, 2017). Research into the heritability of CUD and the molecular mechanisms of cannabinoid action points to a complex interplay between an individual's genetic makeup and the neurobiological changes induced by chronic cannabis exposure.

#### Heritability and Genetic Factors

Evidence suggests that vulnerability to developing addictive behaviors, including CUD, has a genetic component (Dodd, 2007; Winters & Ingwalson, 2022). Family, twin, and adoption studies indicate that genetic factors contribute significantly to the risk of substance use disorders in general (Daley & Douaihy, 2019; Hughes, 1999). While specific genes for CUD have not been definitively identified, research is focused on genes that regulate the ECS, as well as those involved in neurotransmitter systems modulated by cannabinoids, such as the dopamine and serotonin systems (Blum & Trachtenberg, 1988).

A particularly critical area of investigation is the genetic vulnerability to cannabis-induced psychosis (Hall & Degenhardt, 2010). Epidemiological studies have consistently shown that cannabis use, especially during adolescence, increases the risk of developing schizophrenia in genetically predisposed individuals (Häfner, 2005; Zammit et al., 2011; D'Souza, 2023). This suggests a gene-environment interaction, where cannabis acts as a "component cause" or trigger in those with an underlying liability for psychosis (Sewell et al., 2010; D'Souza, 2023). Candidate genes that may moderate this risk include those involved in dopamine metabolism (e.g., COMT) and neurodevelopmental pathways (e.g., AKT1) (Radhakrishnan et al., 2014). For instance, certain polymorphisms may render an individual's dopaminergic system more susceptible to the dysregulating effects of THC, thereby lowering the threshold for psychotic experiences (Hall & Degenhardt, 2010; D'Souza, 2023). The observation that schizophrenia itself has a strong genetic basis, with multiple implicated chromosomes, further supports the hypothesis that cannabis may interact with this pre-existing vulnerability (Dodd, 2007; Buckley & Foster, 2014).

#### Molecular Mechanisms and Neuroadaptation

At the molecular level, cannabis intoxication is initiated by the binding of THC to the CB1 receptor, which triggers a cascade of intracellular signaling events (Lucas et al., 2018). As a G-protein coupled receptor, CB1 activation inhibits adenylyl cyclase, reduces cyclic AMP (cAMP) levels, and modulates various ion channels, ultimately leading to the suppression of neurotransmitter release (Hertz et al., 2014). This acute action is the basis for the immediate psychoactive effects of the drug.

With chronic, heavy use, the brain undergoes neuroadaptive changes in an attempt to maintain homeostasis, a process that underlies the development of tolerance and dependence (Bonnet & Preuss, 2017; Jones et al., 1981). A key molecular adaptation is the desensitization and downregulation of CB1 receptors in various brain regions, including the amygdala and frontal cortex (Cermak, 2020; Bonnet & Preuss, 2017). This reduction in receptor density means that a higher dose of THC is required to achieve the same psychoactive effect, a hallmark of tolerance (Jones et al., 1981; Perera-Diltz, 2015).

These neuroadaptations become particularly evident upon cessation of cannabis use, leading to a withdrawal syndrome (Ramesh et al., 2011). The abrupt absence of THC unmasks the downregulated state of the ECS, resulting in a hyperexcitable state in previously inhibited neural circuits (Bonnet & Preuss, 2017). This contributes to the characteristic symptoms of cannabis withdrawal, such as irritability, anxiety, restlessness, sleep difficulties, and decreased appetite (Ramesh et al., 2011; Connor et al., 2021). The duration of this withdrawal syndrome, which can last for several weeks, appears to correlate with the time required for CB1 receptors to return to their normal density and function (Bonnet & Preuss, 2017).

Furthermore, addiction can be viewed as a form of drug-induced neural plasticity involving persistent cellular and molecular changes (Antonio & Alfredo, 2012). Chronic drug exposure leads to enduring changes in gene expression, mediated by transcription factors, which contribute to the long-lasting behavioral alterations seen in addiction, such as sensitization and craving (Kalivas et al., 2003; Lyvers, 1998). These long-term changes in neural circuitry, particularly within the brain's reward and stress systems, are thought to drive the compulsive drug-seeking behavior that characterizes addiction (Koob, 2020; Roberts & Koob, 1997). The transition from voluntary to compulsive use reflects these profound, and often persistent, molecular changes in the brain (George & Koob, 2017; Koob, 2013).

### Brain Structure and Function

The acute and chronic effects of cannabis are associated with observable changes in both the structure and function of the brain. Neuroimaging techniques, including structural magnetic resonance imaging (MRI) and functional MRI (fMRI), have provided valuable insights into the neural correlates of cannabis intoxication and long-term use, linking specific brain regions to the cognitive and behavioral outcomes associated with the substance (Rivera-Olmos & Parra-Bernal, 2016).

#### Structural Neuroimaging Findings

Chronic, heavy cannabis use, particularly when initiated during adolescence, has been linked to subtle but significant alterations in brain morphology (Hyytiä, 2015; Rivera-Olmos & Parra-Bernal, 2016). Structural MRI studies have investigated changes in gray and white matter volume and density in cannabis users compared to non-using controls.

One of the most consistently reported findings involves the hippocampus, a brain region critical for memory formation and learning (Dodd, 2007; Dervaux, 2013). Several studies have found that long-term cannabis consumers exhibit a dose-dependent reduction in gray matter volume or density in the hippocampus and adjacent parahippocampal regions (Dervaux, 2013). Given the high concentration of CB1 receptors in the hippocampus, this structural change provides a plausible neuroanatomical substrate for the memory impairments frequently observed in chronic users (Araos et al., 2014; Hall, 2012). These deficits primarily affect short-term episodic and working memory (Oomen et al., 2018; Campos et al., 2016).

The amygdala, a key structure in the limbic system involved in processing emotions like fear and anxiety, also shows structural changes in chronic users (Dervaux, 2013). Reductions in amygdala volume have been reported and may be related to the alterations in emotional processing and regulation observed in some cannabis users (Cermak, 2020). Other brain areas, including the frontal lobe, basal ganglia, and cerebellum, have also been implicated, with some studies indicating selective reductions in size or volume (Dodd, 2007). These regions are integral to executive functions, motor control, and reward processing, and structural changes may underlie deficits in these domains (Page, 1983; Rivera-Olmos & Parra-Bernal, 2016). For example, frontal lobe abnormalities are associated with negative symptoms and neurocognitive deficits in schizophrenia, a condition for which cannabis use is a risk factor (Dodd, 2007).

It is important to note that the evidence for structural changes is not entirely consistent, and some of the observed effects may be reversible with prolonged abstinence (Van Gerven Jm et al., 1998). The impact of cannabis on brain structure appears to be most pronounced when use begins during the critical neurodevelopmental period of adolescence (Hyytiä, 2015; Araos et al., 2014).

#### Functional Neuroimaging Findings

Functional neuroimaging studies have been instrumental in elucidating the acute effects of THC on brain activity and connectivity during intoxication, as well as the lasting functional alterations in chronic users even during abstinence.

During acute intoxication, fMRI studies show that THC administration alters brain activation patterns in response to cognitive tasks (Oomen et al., 2018). For example, when performing working memory tasks, cannabis users may show either increased or decreased activation in prefrontal and parietal networks compared to controls (Feinstein et al., 2015). One interpretation of increased activation is that the brain is recruiting additional neural resources to compensate for the drug's impairing effects, thereby maintaining performance accuracy at the cost of neural efficiency (Feinstein et al., 2015). This compensatory mechanism may explain why performance deficits are not always apparent in laboratory settings despite the subjective feeling of impairment (Sulkowski, 1980).

Cannabis intoxication also affects the brain's default mode network (DMN) and other resting-state networks, which are involved in self-referential thought and mind-wandering. Altered connectivity within the DMN and between the DMN and executive control networks may underlie the distorted sense of time, depersonalization, and disorganized thought processes reported during a "high" (Hollister, 1971; Pearlson, 2020).

Long-term cannabis use is associated with persistent changes in brain function. Chronic users often exhibit "hypofrontality," a state of reduced baseline activity in the prefrontal cortex, which is implicated in executive functions such as decision-making, planning, and impulse control (Dodd, 2007; Cadet & Bolla, 1996). This functional deficit is thought to contribute to the "amotivational syndrome" described in some heavy users, characterized by apathy, lack of initiative, and impaired goal-directed behavior (Schmits & Quertemont, 2013; Hall, 2012). These executive dysfunctions and deficits in decision-making are core features of addictive disorders in general (Noël et al., 2010; Bari et al., 2010).

Furthermore, functional imaging has shed light on the neural basis of cannabis-induced psychosis. During intoxication, cannabinoids produce brain activity patterns in key regions like the striatum, hippocampus, and prefrontal cortex that are opposite to those produced by cannabidiol (CBD), a non-psychoactive component of cannabis with potential antipsychotic properties (Sewell et al., 2010; Leweke & Rohleder, 2023). This suggests that the balance of THC and CBD in a given cannabis product can significantly influence its psychotomimetic potential (Niesink & Laar, 2013).

### Developmental Neurobiology

The impact of cannabis on the brain is not uniform across the lifespan; the developing brain, particularly during adolescence, is uniquely vulnerable to the neurotoxic effects of cannabinoids (Hyytiä, 2015; Araos et al., 2014). Adolescence is a critical period of neurodevelopment characterized by significant synaptic pruning, myelination, and maturation of key neural circuits, especially those involving the prefrontal cortex and the endocannabinoid system itself (Sommer & Arango, 2017). Exposure to cannabis during this window can interfere with these normal maturational processes, potentially leading to lasting structural and functional consequences (Rivera-Olmos & Parra-Bernal, 2016; Hyytiä, 2015).

#### Adolescent Vulnerability

The endocannabinoid system plays a crucial role in orchestrating brain development, including neuronal migration, synapse formation, and plasticity (Araos et al., 2014). Chronic exposure to high levels of THC during adolescence can disrupt the delicate balance of this system, interfering with the refinement of neural circuits (Dervaux, 2013). This disruption is thought to be a primary mechanism through which early-onset cannabis use heightens the risk for long-term adverse outcomes (Ashton, 2018; Hoch et al., 2024).

Adolescents who engage in regular, heavy cannabis use show a heightened risk of developing CUD compared to those who start using in adulthood (Hall, 2012; Taylor & Beckmann, 2021). This increased vulnerability to addiction is believed to stem from the effects of THC on the still-maturing dopamine reward system, leading to more profound and enduring changes in motivation and reward-seeking behavior (Winters & Ingwalson, 2022; George & Koob, 2017).

Furthermore, the cognitive impairments associated with cannabis appear to be more severe and persistent in individuals who begin using heavily during their teenage years (Ashton, 2018; Hall, 2012). Longitudinal studies have shown that early and frequent cannabis use is associated with impaired educational achievement, a decline in socioeconomic status, and subtle but lasting deficits in cognitive domains such as attention, memory, and executive function (Hall, 2012; Ashton, 2018; Copeland et al., 2014). While some cognitive functions may improve with abstinence, evidence suggests that heavy adolescent use can lead to long-term impairment of life and mental functioning that may not be fully reversible (Ashton, 2018; Van Gerven Jm et al., 1998). The brain's greater plasticity during adolescence makes it more susceptible to the neurotoxic effects of drugs, potentially leading to permanent alterations in brain structure and function (Hyytiä, 2015; Araos et al., 2014).

#### Cannabis Use and the Onset of Psychotic Disorders

One of the most concerning developmental impacts of adolescent cannabis use is its strong association with the emergence of psychotic disorders, particularly schizophrenia (Radhakrishnan et al., 2014; D'Souza, 2023). Numerous longitudinal studies have demonstrated a dose-response relationship: the earlier the age of initiation and the heavier the use, the higher the risk of developing psychosis later in life (Hall & Degenhardt, 2010; Zammit et al., 2011). Cannabis use can prematurely trigger the onset of schizophrenia, on average several years earlier than in non-users, especially in vulnerable individuals (Häfner, 2005; Radhakrishnan et al., 2014).

The "two-hit" or "multiple-hit" hypothesis of schizophrenia suggests that a genetic predisposition combined with environmental stressors (such as adolescent cannabis use) is necessary for the illness to manifest (Dodd, 2007). Cannabis may act as a crucial environmental "hit" during the vulnerable period of adolescent brain maturation, disrupting neurodevelopmental trajectories and unmasking a latent psychosis (Sommer & Arango, 2017; Häfner, 2005). The neurobiological mechanisms are thought to involve the dysregulation of dopaminergic and glutamatergic systems, which are already implicated in the pathophysiology of schizophrenia (Dodd, 2007; Potvin et al., 2004).

For individuals who already have an established psychotic disorder, continued cannabis use worsens the course of the illness, leading to an increase in positive symptoms (e.g., hallucinations, delusions), higher relapse rates, and more frequent hospitalizations (Thomas, 1993; Hall & Degenhardt, 2010; Sewell et al., 2010). While some patients report using cannabis to "self-medicate" negative symptoms or improve mood, this hypothesis is unlikely to fully explain the strong association, and the overall evidence points to a detrimental effect on the illness course (Hall & Degenhardt, 2010; Chambers, 2009). The increased risk is particularly pronounced with the use of high-potency cannabis products, which have a higher THC-to-CBD ratio (Hoch et al., 2024; Taylor & Beckmann, 2021).

### Treatment Mechanisms

While the primary management of acute cannabis intoxication is supportive care, and treatment for CUD largely relies on psychosocial interventions, understanding the underlying biological mechanisms is crucial for developing targeted pharmacotherapies (Sarkar et al., 2023; Pytell & Rastegar, 2025). Currently, no medications are specifically approved for the treatment of CUD or cannabis withdrawal, but research is exploring several avenues based on the neurobiology of cannabinoid effects (Pytell & Rastegar, 2025; Taylor & Beckmann, 2021).

#### Management of Acute Intoxication

Acute cannabis intoxication typically results in a transient condition that resolves as the drug is metabolized and cleared from the body (Sarkar et al., 2023). Management is largely supportive, focusing on reassurance and providing a calm, low-stimulation environment (Sarkar et al., 2023). In cases of severe anxiety, panic attacks, or agitation, benzodiazepines like lorazepam or clonazepam may be administered for their anxiolytic and sedative effects (Sarkar et al., 2023; Adès & Lejoyeux, 1993). These agents enhance the effect of the neurotransmitter GABA at the GABA-A receptor, producing a calming effect on the central nervous system, which can counteract the hyperexcitability and anxiety sometimes induced by high doses of THC (Hertz et al., 2014; Nelson & Chouinard, 1999).

In the rare event of a severe, cannabis-induced psychotic episode, short-term use of antipsychotic medications may be necessary (Sarkar et al., 2023; Thomas, 1993). These drugs primarily act by blocking dopamine D2 receptors, thereby reducing the excessive dopaminergic activity thought to underlie psychotic symptoms (Dodd, 2007; Reid et al., 1997). This approach directly targets the neurochemical imbalance precipitated by THC's effects on the mesolimbic dopamine system (Häfner, 2005).

A novel approach for treating acute intoxication involves the development of CB1 receptor antagonists (Skolnick & Crystal, 2019). These compounds are designed to directly block the action of THC at the CB1 receptor, thereby reversing the intoxicating effects. While promising, this area of research is still in early stages, and concerns about potential adverse effects, such as pro-depressant or anxiogenic reactions, need to be addressed (Skolnick & Crystal, 2019).

#### Pharmacotherapy for Cannabis Withdrawal and CUD

The cannabis withdrawal syndrome is characterized by symptoms such as anxiety, irritability, insomnia, and craving, which can precipitate relapse (Connor et al., 2021; Ramesh et al., 2011). Pharmacological strategies aim to alleviate these symptoms and support abstinence.

**Cannabinoid Agonist Therapy:** One approach, analogous to methadone maintenance for opioid dependence, is substitution therapy with cannabis agonists (Moore et al., 2008). Synthetic THC preparations (e.g., dronabinol) or cannabis-based medicinal extracts (e.g., nabiximols) can be used to mitigate withdrawal symptoms by providing a controlled, tapering dose of a cannabinoid agonist (Bonnet & Preuss, 2017). This strategy helps to stabilize the downregulated ECS and allows for a more gradual re-equilibration, reducing the severity of withdrawal (Jones et al., 1981).

**Modulation of Other Neurotransmitter Systems:** Several medications that target neurotransmitter systems affected by cannabis are being investigated.
*   **Gabapentin:** This anticonvulsant medication modulates calcium channels and affects GABAergic and glutamatergic systems. Promising results suggest it may reduce the symptoms of cannabis withdrawal, particularly insomnia and anxiety (Bonnet & Preuss, 2017; Tiglao et al., 2021).
*   **N-acetylcysteine (NAC):** This compound is thought to restore glutamate homeostasis in the nucleus accumbens, which is disrupted by chronic drug use. Preliminary studies suggest NAC may be helpful for decreasing cravings and reducing the risk of relapse in adolescents with CUD (Taylor & Beckmann, 2021).
*   **Antidepressants:** Given the overlap between cannabis withdrawal symptoms and depression (e.g., depressed mood, insomnia, irritability), antidepressants have been studied, but with mixed results (Bonnet & Preuss, 2017). Some agents like venlafaxine have been reported to potentially worsen withdrawal symptoms, while others like mirtazapine may be beneficial for insomnia (Bonnet & Preuss, 2017; Halle & Del Medico, 1991).

The most effective therapy modalities for CUD remain psychosocial, including motivational enhancement therapy, cognitive behavioral therapy (CBT), and family-based therapy (Taylor & Beckmann, 2021; Moore et al., 2008). These approaches help individuals develop coping skills, manage cravings, and address the underlying psychological factors contributing to their substance use (Franken & Wiers, 2013).

### Future Directions

Despite significant advances in understanding the neurobiology of cannabis intoxication, many questions remain unanswered. The current body of literature, while highlighting key mechanisms, also reveals numerous gaps that future research must address to refine our knowledge and improve clinical practice. The increasing legalization of cannabis for both medical and recreational purposes makes this research particularly urgent (Hoch et al., 2024).

A primary challenge is the heterogeneity of cannabis itself and its users. Cannabis is not a single compound but a complex mixture of over 100 cannabinoids, with varying ratios of THC and cannabidiol (CBD) (Hoch et al., 2024; D'Souza, 2023). CBD has been shown to counteract some of the adverse psychological effects of THC, including anxiety and psychosis (Niesink & Laar, 2013; Schoedel & Harrison, 2012). Future studies must systematically investigate how different THC:CBD ratios and the presence of other cannabinoids and terpenes modify the acute and chronic effects of cannabis on the brain and behavior (Pearlson, 2020). This knowledge is crucial for public health messaging and for developing safer cannabis-based medicines (Solimini et al., 2017).

Longitudinal studies are critically needed to clarify the causal nature of the associations between cannabis use and adverse mental health outcomes (Thomas, 1993). While the link with psychosis is strong, particularly for adolescent-onset use, the precise mechanisms and the factors determining individual vulnerability are not fully understood (Hall & Degenhardt, 2010; Radhakrishnan et al., 2014). Large-scale, prospective studies that combine genetic screening, neuroimaging, and detailed environmental assessments are required to untangle the complex interplay between genetic predisposition, cannabis use, and the onset of psychiatric disorders like schizophrenia and depression (Sommer & Arango, 2017; D'Souza, 2023).

Neuroimaging research should continue to explore the acute and long-term effects of cannabis on brain structure, function, and connectivity. Advanced imaging techniques can help to characterize the neural basis of cognitive impairment, emotional dysregulation, and psychosis risk (Rivera-Olmos & Parra-Bernal, 2016). It is particularly important to determine the extent to which cannabis-related brain changes are reversible with abstinence and whether early intervention can mitigate long-term damage, especially in adolescent users (Van Gerven Jm et al., 1998; Hyytiä, 2015).

The development of effective pharmacotherapies for CUD and cannabis withdrawal remains a high priority (Pytell & Rastegar, 2025). Future research should build on promising preliminary findings with agents like gabapentin and N-acetylcysteine and explore novel targets within the ECS and related neurotransmitter systems (Bonnet & Preuss, 2017; Taylor & Beckmann, 2021). The potential therapeutic application of cannabinoids themselves, such as CBD for its anxiolytic and antipsychotic properties, warrants further rigorous investigation in controlled clinical trials (Leweke & Rohleder, 2023; Ashton et al., 2005).

Finally, there is a need to better understand the biological basis of heterogeneity in cannabis intoxication. Why do some individuals experience euphoria and relaxation while others experience severe anxiety and paranoia (Thomas, 1993)? Factors such as genetic background, personality traits, previous psychiatric history, and the context of use (set and setting) all likely play a role (George & Koob, 2017; Pechnick et al., 2014). Integrating biological measures with psychological and social assessments will be key to developing a more personalized understanding of cannabis's effects and risks.

### Conclusion

The biological and neurological basis of cannabis intoxication is a multifaceted process centered on the profound influence of exogenous cannabinoids, primarily THC, on the brain's endogenous cannabinoid system. This interaction initiates a complex cascade of neurochemical changes, fundamentally altering the delicate balance of dopamine, serotonin, GABA, and glutamate neurotransmission (Araos et al., 2014; Dodd, 2007; Sewell et al., 2010). The resulting subjective experience of intoxication—encompassing euphoria, relaxation, perceptual alterations, and cognitive impairment—is a direct reflection of THC's widespread modulatory action across critical brain regions, including the mesolimbic reward pathway, hippocampus, prefrontal cortex, and cerebellum (Dervaux, 2013; Pearlson, 2020).

The acute, transient state of intoxication provides a window into the brain's vulnerability to cannabinoid influence. Chronic exposure leads to neuroadaptive processes, such as CB1 receptor downregulation, which underlie the phenomena of tolerance and the emergence of a clinically significant withdrawal syndrome upon cessation (Bonnet & Preuss, 2017; Ramesh et al., 2011). The evidence strongly indicates that the developing adolescent brain is particularly susceptible to these effects, with early and heavy use constituting a significant risk factor for the development of CUD, persistent cognitive deficits, and the precipitation of severe mental illnesses, most notably schizophrenia, in vulnerable individuals (Hoch et al., 2024; Ashton, 2018; Radhakrishnan et al., 2014).

While our understanding of these mechanisms has advanced significantly, the clinical and public health implications are still unfolding. The variability in individual responses, the complex composition of the cannabis plant, and the influence of genetic and environmental factors create a heterogeneous landscape of risk and effect. Current treatments remain limited, with a heavy reliance on psychosocial interventions and a pressing need for effective, biologically-informed pharmacotherapies (Pytell & Rastegar, 2025). As societal norms and legal frameworks surrounding cannabis continue to evolve, a robust and nuanced understanding of its neurobiological impact is more critical than ever. Continued research into these fundamental mechanisms is essential to guide evidence-based policy, inform public health education, and develop effective strategies for the prevention and treatment of cannabis-related harm.

## References

1. Abdelsayed, S., Acevedo, R., & Clemow, L. (2017). Is sleep deprivation associated with behavioral changes in children and adolescents?. Evidence-Based Practice. https://doi.org/10.1097/01.ebp.0000541629.93211.cb
2. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
3. Abhilash, K. P., Jha, A., Bandhyopadhyay, R., & Victor, P. (2014). Hypoglycemia - A rare complication of carbamazepine overdose. Indian Journal of Pharmacology. https://doi.org/10.4103/0253-7613.144941
4. Abi‐Jaoude, E., Stall, N. M., & Rochon, P. A. (2018). Psychotropic drugs for the behavioural and psychological symptoms of dementia: no free ride. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.181486
5. Adams, C. E., Wilson, P., Gilbody, S., Bagnall, A., & Lewis, R. (2000). Drug treatments for schizophrenia. Quality in Health Care. https://doi.org/10.1136/qhc.9.1.73
6. Akiskal, H. S. (1980). Characterological Depressions. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1980.01780200055006
7. Akpınar, A., & Demirdaş, A. (2014). Dissociative Identity Disorder Presenting as a Suicide Attempt or Drug Overdose: A Case Report. Erciyes Medical Journal. https://doi.org/10.5152/etd.2014.7201
8. Al-Nesf, M., & Mobayed, H. (2014). Two cases of food-dependent exercise-induced anaphylaxis with different culprit foods. Annals of Thoracic Medicine. https://doi.org/10.4103/1817-1737.124443
9. Albalawi, R., Alsahli, H., Almutairi, N. B., & Alhashemi, M. (2024). Acute psychosis and behavioural changes with seizure-like hyperactive psychomotor activity secondary to isotretinoin initiation in a healthy young male: case report. Annals of Medicine and Surgery. https://doi.org/10.1097/ms9.0000000000001726
10. Alexi, T., Faull, R. L. M., & Hughes, P. E. (2000). Variable Susceptibility to Neurotoxicity of Systemic 3-Nitropropionic Acid. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-692-8_9
11. Alghamdi, B., Zrari, M., Elahi, A. M. N., Alwagdani, M., Alghamdi, E. A. S., Moafa, H., Miran, S., Alamoudi, S., Alshahrani, K., Binnwejim, M., & jaafari, M. A. (2018). Substance abuse and its psychiatric effect on adolescence. International Journal of Community Medicine and Public Health. https://doi.org/10.18203/2394-6040.ijcmph20182450
12. Alloy, L. B., & Abramson, L. Y. (2010). Cyclothymic Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0249
13. Altınbaş, K., Can, A. A., Kurt, E., & Uygur, N. (2014). Delirious mania: Clinical course and treatment. Journal of Mood Disorders. https://doi.org/10.5455/jmood.20140901035042
14. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
15. Anani, S., Goldhaber, G., Wasserstrum, Y., Dagan, A., & Segal, G. (2018). The ‘SILENT Alarm’: When History Taking Reveals a Potentially Fatal Toxicity. European Journal of Case Reports in Internal Medicine. https://doi.org/10.12890/2018_000843
16. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). None. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s
17. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). ORAL PRESENTATION – ABSTRACTS. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s.1
18. Anghelescu, G., Bojescu, A. A., Populeanu, R., Ionică, M., Vlădescu, M., Macovei, R. A., & Caragea, G. (2018). Multiple reactions monitoring for cocaine and ethylbenzoylecgonine to increase the signal/noise ratio in mass spectrometry analysis. Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies IX. https://doi.org/10.1117/12.2322569
19. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
20. Antón, R., Uribe-viloria, N. D., Sánchez, A. A., Calzón, M. D. L., García, M. G., Astorga, A. Á., Gallego, H. D. L. R., Sánchez, S. G., Canga, C. N., Ojeda, G. M., & Cegama, F. D. U. L. D. (2017). Clinical Features and Diagnosis of Alcoholic Hallucinosis. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.2152
21. Araos, P., Calado, M., Vergara‐Moragues, E., Pedraz, M., Pavón, F. J., & Fonseca, F. R. D. (2014). Adicción a cannabis: bases neurobiológicas y consecuencias médicas.
22. Ariaee, N., & Toussi, A. G. (2014). Psychological Effects of Alcohol Abuse. Asia pacific journal of medical toxicology. https://doi.org/10.22038/apjmt.2014.2898
23. Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium. Gazi Medical Journal.
24. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2016). Nonconvulsive status epilepticus and psychotic symptoms: case report Stato epilettico non convulsivo e sintomi psicotici: caso clinico.
25. As, B., On, C., & NIu, R. (2014). [Bipolar depression in the clinic of schizophrenia].. PubMed.
26. Asadi, S. (2023). The Role of Bio- Psychological Factors in Sleep Anxiety and Hypomania Disorder. https://doi.org/10.31579/2835-2882/016
27. Aschenbrenner, D. S. (2018). First Approval of a Drug Derived from Marijuana. AJN American Journal of Nursing. https://doi.org/10.1097/01.naj.0000546370.05314.c8
28. Ashton, J. C. (2018). Is Cannabis Harmless? Focus on Brain Function. Current Drug Research Reviews. https://doi.org/10.2174/2589977511666180809165622
29. Ayala, L., Gómez‐Revuelta, M., Requena, C. M., Acilu, E. S. D. A. G. D., Olivares, O. P., Ruíz, M. J., Morales, N. N., Martin, M., Zufiaurre, M. L., Hernández, B., Itoiz, A. A., Peña, M., & González‐Pinto, A. (2017). Clozapine: Since the very beginning?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1402
30. Ayşe, H., Hakkı, ©., Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium?. Gazi Medical Journal. https://doi.org/10.12996/gmj.2017.45
31. Babi, M.-A., Robinson, C. P., & Maciel, C. B. (2017). A spicy status: Synthetic cannabinoid (spice) use and new-onset refractory status epilepticus—A case report and review of the literature. SAGE Open Medical Case Reports. https://doi.org/10.1177/2050313x17745206
32. Baldaçara, L., Ferrari, M. D. C., Monteiro, B., Uchida, R. R., & Sanches, M. (2007). Hypomania Induced by Atypical Antipsychotics among Schizophrenic Patients: Report of Three Cases. Pharmacopsychiatry. https://doi.org/10.1055/s-2007-984388
33. Baldaçara, L., Ramos, A., & Castaldelli-Maia, J. M. (2023). Managing drug-induced psychosis. International Review of Psychiatry. https://doi.org/10.1080/09540261.2023.2261544
34. Balhara, Y. P. S., Mohan, I., Sagar, R., & Chawla, J. (2006). Chronic mania: An unexpectidly long episode?. Indian Journal of Medical Sciences. https://doi.org/10.4103/0019-5359.25681
35. Banerjee, S. (2012). ADHD in Children and Adolescents: A Good Practice Guidance. InTech eBooks. https://doi.org/10.5772/28404
36. Bansode, P. V., Pathak, S. D., & Wagh, S. P. (2013). DENTIN HYPERSENSITIVITY - REVISITED. Journal of Evolution of Medical and Dental Sciences. https://doi.org/10.14260/jemds/1160
37. Barbosa, M. O. S., Silva, F. L. C., Castro, J. D. O., Marino, L. D. B., Silva, V. D. S., Pinho, R. C., & Bonfim, Y. C. (2018). PROCESSO DE ENFERMAGEM EM PACIENTE COM ESQUIZOFRENIA HEBEFRÊNICA: UM RELATO DE CASO. 13º Congresso Internacional Rede Unida.
38. Barea, M. V., Arévalo, A. J., Pérez, I. C., & Melero, M. P. V. (2025). Dual pathology and Takotsubo syndrome. A case report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2025.1000
39. Bari, A., Robbins, T. W., & Dalley, J. W. (2010). Impulsivity. Neuromethods. https://doi.org/10.1007/978-1-60761-934-5_14
40. Barnes, T. R. E., & Paton, C. (2011). Do antidepressants improve negative symptoms in schizophrenia?. BMJ. https://doi.org/10.1136/bmj.d3371
41. Barnovitz, M. A. L. C. M., & Joglekar, P. M. (2007). Medical Psychiatry: The Quick Reference.
42. Baronia, R. B. (2015). Oral Hydrocodone Induced Acute Psychosis in an Adult Male: A CaseReport.. Journal of Clinical Case Reports. https://doi.org/10.4172/2165-7920.1000535
43. Barrio, A. G. D. (2018). Intervención Psicoterapéutica Integrada y Transdiagnóstica en los Trastornos de la Conducta Alimentaria. Revista de Psicoterapia. https://doi.org/10.33898/rdp.v29i110.248
44. Barteček, R., Kašpárek, T., & Češková, E. (2011). Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia. Open Medicine. https://doi.org/10.2478/s11536-011-0055-8
45. Barz, H. (2010). Question Mark Over Hypocomplementemia. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2010.0349b
46. Basu, A., Jagtiani, A., & Gupta, R. (2014). Catatonia in mixed alcohol and benzodiazepine withdrawal. Journal of Pharmacology and Pharmacotherapeutics. https://doi.org/10.4103/0976-500x.142449
47. Batinić, B., Duišin, D., & Vukosavljevic-Gvozden, T. (2017). Neurobiological bases for impulsive and compulsive behaviour: Implications for pharmacological and psychological interventions. Engrami. https://doi.org/10.5937/engrami1701017b
48. Baweja, R., Sedky, K., & Lippmann, S. (2010). Clozapine associated delirium. Eastern Journal Of Medicine.
49. Baxter, P. (2015). States of consciousness: new insights and further questions. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.12666
50. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
51. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
52. Bell, D. S. (1973). The Experimental Reproduction of Amphetamine Psychosis. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1973.04200010020003
53. Bellamkonda, P., Mansou, G., Tantoush, H., & Abuzaid, A. (2014). Marijuana Induced Transient Global Amnesia.
54. Bellamy, S. E., Loor, B., & Gutierrez-Castillo, M. (2023). A Case of Cannabinoid Hyperemesis Syndrome and Acute Kidney Injury: A Review of the Literature. Cureus. https://doi.org/10.7759/cureus.34350
55. Bembenick, K. N., Mathew, J., Heisler, M., Siddaiah, H., Moore, P., Robinson, C. L., Kaye, A. M., Shekoohi, S., Kaye, A. D., & Varrassi, G. (2024). Hyponatremia With Anticonvulsant Medications: A Narrative Review. Cureus. https://doi.org/10.7759/cureus.57535
56. Benbadis, S. R., Sanchez‐Ramos, J., Bozorg, A., Giarratano, M., Kalidas, K., Katzin, L., Robertson, D., Vu, T., Smith, A., & Zesiewicz, T. A. (2014). Medical marijuana in neurology. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2014.985209
57. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
58. Besag, F., Gobbi, G., Aldenkamp, A. P., Caplan, R., Dunn, D. W., & Sillanpää, M. (2016). Psychiatric and Behavioural Disorders in Children with Epilepsy (ILAE Task Force Report): Subtle behavioural and cognitive manifestations of epilepsy. Epileptic Disorders. https://doi.org/10.1684/epd.2016.0816
59. Birkenhäger-Gillesse, E. G., & Poel, M. F. P. V. D. (2008). [Carbon monoxide poisoning; psychotic depression brought on by a new kitchen].. Tijdschrift voor psychiatrie.
60. Bismuth, C., Bellec, L., Dally, S., & Lagier, G. (1980). [Benzodiazepine physical dependence. 6 cases (author's transl)].. PubMed.
61. Biyani, G., Vandana, S., & Bhatia, P. (2015). Opioids induced serotonin toxicity? Think again. Indian Journal of Anaesthesia. https://doi.org/10.4103/0019-5049.160979
62. Blum, K., & Trachtenberg, M. C. (1988). Alcoholism: Scientific Basis of a Neuropsychogenetic Disease. International Journal of the Addictions. https://doi.org/10.3109/10826088809058839
63. Bogaczewicz, A., Bogaczewicz, J., Woźniacka, A., & Sobów, T. (2014). EPA-1255 – Behavioral symptoms in patients with systemic lupus erythematosus induced by chloroquine-a report of two cases. European Psychiatry. https://doi.org/10.1016/s0924-9338(14)78492-5
64. Boggs, C. L., Ripple, M., Ali, Z., Brassell, M., Levine, B., Jufer‐Phipps, R., Doyon, S., & Fowler, D. R. (2013). Anaphylaxis After the Injection of Buprenorphine. Journal of Forensic Sciences. https://doi.org/10.1111/1556-4029.12161
65. Bokor, G., & Anderson, P. (2014). Ketamine. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190014525754
66. Bonnet, U., & Preuss, U. W. (2017). The cannabis withdrawal syndrome: current insights. Substance Abuse and Rehabilitation. https://doi.org/10.2147/sar.s109576
67. Bonotis, K. (2013). Manifestations of Psychotic Symptomatology during Ex-cessive Internet Use. Psychology and Behavioral Sciences. https://doi.org/10.11648/j.pbs.20130202.12
68. Botello, M. C., Navarro, M. C., Vera, M. M., Sánchez, J. H., & López, F. M. (2016). Cannabis and cyclical vomiting. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.995
69. Bousoño, M., Baca, E., Alvarez, E., Eguiluz, I., Martin, M., Roca, M., & Urretavizcaya, M. (2008). Complicaciones de la depresión a largo plazo. Actas Españolas de Psiquiatría.
70. Boyle, J., Danjou, P., Alexander, R., Calder, N., Gargano, C., Agrawal, N., Fu, I., McCrea, J. B., & Murphy, M. G. (2008). Tolerability, pharmacokinetics and night‐time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2008.03331.x
71. Bradic, L., Lokmić-Pekić, I., & Dzevad, B. (2018). Psychiatric comorbidity in patients with posttraumatic stress disorder and enduring personality change after catastrophic experience. https://doi.org/10.26226/morressier.5b68175cb56e9b005965c22b
72. Branin, J., Jazi, A. N., Shebak, S. S., & Kim, K. (2017). Alcohol Related Cognitive Impairments: an Overview for Clinical Practitioners. Journal of Geriatrics and Palliative Care. https://doi.org/10.13188/2373-1133.1000020
73. Brashear, A., Sweadner, K. J., Cook, J., Swoboda, K. J., & Ozelius, L. J. (2014). ATP1A3-Related Neurologic Disorders. University of Washington, Seattle eBooks.
74. Brašić, J. R. (1998). Hallucinations. Perceptual and Motor Skills. https://doi.org/10.2466/pms.1998.86.3.851
75. Breuer, L., Kasper, B. S., Schwarze, B., Gschossmann, J. M., Kornhuber, J., & Müller, H. (2015). “Herbal seizures” – atypical symptoms after ibogaine intoxication: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-015-0731-4
76. Brignole, M., Alboni, P., Benditt, D. G., Bergfeldt, L., Blanc, J., Thomsen, P. E. B., Dijk, J. G. V., Fitzpatrick, A., Hohnloser, S. H., Janousek, J., Kapoor, W. N., Kenny, R. A., Kułakowski, P., Masotti, G., Moyá, A., Raviele, A., Sutton, R., Theodorakis, G., Ungar, A., & Wieling, W. (2004). Guidelines on Management (diagnosis and treatment) of syncope ? update 2004. EP Europace. https://doi.org/10.1016/j.eupc.2004.08.008
77. Briones, T., & Alejandrina, A. (2018). Efecto de la hipnosis activa sobre la fatiga y optimismo en niños con leucemia linfoblastica aguda..
78. Broderick, P., & Benjamin, A. B. (2004). Caffeine and psychiatric symptoms: a review.. PubMed.
79. Brody, D. L. (2019). How Do You Make the Diagnosis of Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0003
80. Bruun, T. G. (1993). [Abuse potential during use and withdrawal psychosis after treatment with the hypnotic zolpidem (Stilnoct)].. PubMed.
81. BS, A. H., & BA, M. F. (2018). Glossary. https://doi.org/10.1002/9781119449737.gloss
82. BS, R. A., & Veronica, A. S. (2016). Synthetic Cannabinoids and Dysphonia: A Case Report. Journal of General Practice. https://doi.org/10.4172/2329-9126.1000220
83. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
84. Buitelaar, J. K. (2003). Why Have Drug Treatments Been So Disappointing?. Novartis Foundation symposium. https://doi.org/10.1002/0470869380.ch14
85. Bulacia, A. V. (2016). [Psychiatric complications of cannabis use].. PubMed.
86. Burkart, J., Jong, M. C., Ilenkyo, L., Verwer, C., Weber, S., Keller, T., & Klement, P. (2017). P172 Results of a randomised controlled trial with a homeopathic complex medicinal product in children with sleep disorders and restlessness. https://doi.org/10.1136/archdischild-2017-313273.260
87. Burkhart, P. W. M. K. K. (2014). Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies. Journal of Blood Disorders & Transfusion. https://doi.org/10.4172/2155-9864.1000195
88. Bush, F. (2015). OPTIONS for Clinical Intervention in Sexual Decisionmaking.. PubMed.
89. Bustos, W. P. V., & Vásquez, A. P. G. (2018). Intoxicación oral por benzodiacepinas. Reporte de caso y revisión bibliográfica.
90. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Les troubles de l'humeur. Le point sur... Psychologie.
91. Cadet, J. L., & Bolla, K. I. (1996). Chronic cocaine use as a neuropsychiatric syndrome: A model for debate. Synapse. https://doi.org/10.1002/(sici)1098-2396(199601)22:1<28::aid-syn3>3.0.co;2-k
92. Cadet, J. L., & Bolla, K. I. (1996). Chronic cocaine use as a neuropsychiatric syndrome: A model for debate. Synapse. https://doi.org/10.1002/(sici)1098-2396(199601)22:1<28::aid-syn3>3.3.co;2-k
93. Cahill, C., Malhi, G. S., Ivanovski, B., Lagopoulos, J., & Cohen, M. (2006). Cognitive compromise in bipolar disorder with chronic cannabis use: cause or consequence?. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.6.4.591
94. Calvani, M., Anania, C., Cuomo, B., D’Auria, E., Decimo, F., Indirli, G. C., Mastrorilli, V., Santoro, A., Sartorio, M. U. A., & Veronelli, E. (2020). Summation anaphylaxis: A challenging diagnosis. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13347
95. Campos, M. W., Serebrisky, D., & Castaldelli-Maia, J. M. (2016). Smoking and Cognition. Current Drug Abuse Reviews. https://doi.org/10.2174/1874473709666160803101633
96. Capaldi, D. M., & Kim, H. K. (2014). Comorbidity of Depression and Conduct Disorder. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199797004.013.015
97. Carbone, M. G., Tagliarini, C., Rocca, F. D., Flamini, W., Pagni, G., Tripodi, B., Marazziti, D., & Maremmani, I. (2021). Protracted Hiccups Induced by Aripiprazole and Regressed after Administration of Gabapentin. Case Reports in Psychiatry. https://doi.org/10.1155/2021/5567152
98. Carson-DeWitt, R. (2000). Treatments for Parkinson's disease.. PubMed.
99. Catalano, G., Catalano, M. C., & Rodríguez, R. (1997). Dystonia Associated With Crack Cocaine Use. Southern Medical Journal. https://doi.org/10.1097/00007611-199710000-00017
100. Ceelen, M., Das, C. K., Dorn, T., & Jong, J. T. H. D. (2009). [Cocaine use and sudden death: excited delirium syndrome].. PubMed.
101. Cermak, T. L. (2020). The Impacts of Ongoing Marijuana Use on the Mind: Section 2. Cambridge University Press eBooks. https://doi.org/10.1017/9781108653428.009
102. Cerón-Apipilhuasco, A., Loría-Castellanos, J., & Gómez-Bañuelos, L. V. (2023). Intoxicaciones delictivas. Anales Médicos de la Asociación Médica del Centro Médico ABC. https://doi.org/10.24875/amh.m23000027
103. Chambers, R. A. (2009). A Nicotine Challenge to the Self-Medication Hypothesis in a Neurodevelopmental Animal Model of Schizophrenia. Journal of Dual Diagnosis. https://doi.org/10.1080/15504260902869808
104. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
105. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
106. Chaudhry, H., Arshad, N., Niaz, S., Cheema, F., Iqbal, M., & Mufti, K. (2005). Fifteen-year follow-up of conversion disorder. International Psychiatry. https://doi.org/10.1192/s1749367600007517
107. Chawla, J. M., Rao, R., & Sagar, R. (2006). Baclofen-Induced Psychosis. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1h202
108. Chen, D., & LaFrance, W. C. (2018). Epilepsy and Seizures. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615372423.sy10
109. Chen, S.-H., Tsai, M., Tseng, Y., Tseng, Y., Lui, C., & Chuang, Y. (2010). Star fruit intoxication in a patient with moderate renal insufficiency presents as a posterior reversible encephalopathy syndrome.. PubMed.
110. Chen, W., & Tsai, H.-C. (2010). Delayed Encephalopathy Following Carbon Monoxide Poisoning. 北市醫學雜誌. https://doi.org/10.6200/tcmj.2010.7.4.05
111. Chernysheva, I. V., & Borodin, D. D. (2013). [Depressive state of rats in conditions of chronic combined stress caused by the combination of differently modal stressors].. PubMed.
112. Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023). Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation. Cambridge Quarterly of Healthcare Ethics. https://doi.org/10.1017/s0963180123000270
113. Chou, C. J. (2009). Mixed Episodes with Psychotic Features. CNS Spectrums. https://doi.org/10.1017/s1092852900003886
114. Chue, P., & Lalonde, J. (2014). Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s43404
115. Cianchetti, C., Pruna, D., & Ledda, M. (2013). Epileptic seizures and headache/migraine: A review of types of association and terminology. Seizure. https://doi.org/10.1016/j.seizure.2013.05.017
116. Ciraulo, D. M., & Ciraulo, D. A. (2008). Benzodiazepines <i>Misuse, Abuse, and Dependence</i>. https://doi.org/10.1093/oso/9780195300550.003.0019
117. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Consciousness disturbances during poisonings: pathophysiology, clinical picture, and basic principles of diagnosis and management].. PubMed.
118. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Rare consciousness disturbances in toxicological practice: akinetic mutism, somnambulism, locked-in syndrome, and psychogenic coma].. PubMed.
119. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Toxicant-induced and drug-induced coma neurotoxicological issues of general anesthesia].. PubMed.
120. Cohen, K., & Weinstein, A. (2018). Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2018.00162
121. Cole, J., & Katz, M. M. (1964). THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW.. PubMed.
122. Cole, J., & Katz, M. M. (1964). The Psychotomimetic Drugs. JAMA. https://doi.org/10.1001/jama.1964.03060230086021
123. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
124. Conde, I. L., Fernández‐Montalvo, J., Ustárroz, J. T., González, N. L., & López‐Goñi, J. J. (2010). Rendimiento neuropsicológico en la adicción a la cocaína: una revisión crítica. Revista de Neurología. https://doi.org/10.33588/rn.5107.2010395
125. Connell, J., Oldham, M., Pandharipande, P. P., Dittus, R. S., Wilson, A. M., Mart, M. F., Heckers, S., Ely, E. W., & Wilson, J. E. (2022). Malignant Catatonia: A Review for the Intensivist. Journal of Intensive Care Medicine. https://doi.org/10.1177/08850666221114303
126. Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021). Clinical management of cannabis withdrawal. Addiction. https://doi.org/10.1111/add.15743
127. Consroe, P., & Snider, S. R. (2019). Therapeutic Potential of Cannabinoids in Neurological Disorders * , †. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-2
128. Conti, P. C. R., Cunha, C. O., Conti, A. C. D. C. F., Bonjardim, L. R., Stuginski‐Barbosa, J., & Costa, Y. M. (2023). Secondary bruxism: A valid diagnosis or just a coincidental finding of additional masticatory muscle activity? A narrative review of literature. Journal of Oral Rehabilitation. https://doi.org/10.1111/joor.13592
129. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
130. Copeland, J., Clement, N., & Swift, W. (2014). Cannabis use, harms and the management of cannabis use disorder. Neuropsychiatry. https://doi.org/10.2217/npy.13.90
131. Coscas, S., Benyamina, A., Reynaud, M., & Karila, L. (2013). [Psychiatric complications of cannabis use].. PubMed.
132. Covington, H. E., & Miczek, K. A. (2010). Binge Drug Taking. Neuromethods. https://doi.org/10.1007/978-1-60761-934-5_15
133. Crippa, M., Toffoletto, F., & Torri, D. (2007). [Interactions between alcohol and work exposure to chemical substances].. La Medicina del lavoro.
134. Crocker, C. E., Carter, A., Emsley, J. G., Magee, K., Atkinson, P., & Tibbo, P. G. (2021). When Cannabis Use Goes Wrong: Mental Health Side Effects of Cannabis Use That Present to Emergency Services. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2021.640222
135. Crome, I., & Myton, T. (2004). Pharmacotherapy in dual diagnosis. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.10.6.413
136. Cruz, M. C. D., Camargo, R. P. D., Cruz, L. C. D., Schiefelbein, N., Cruz, D. M. D., & Cruz, M. C. C. D. (2020). Migrânea: revisão de literatura. ARCHIVES OF HEALTH INVESTIGATION. https://doi.org/10.21270/archi.v10i2.4670
137. Csernus, I., Gaszner, P., Fülöp, B., & Gaszner, G. (2004). [Schizoid psychosis during cannabis intake (case report)].. PubMed.
138. Cummings, P. M., Trelka, D. P., & Springer, K. M. (2013). Poisoning. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511920905.007
139. Cunningham, S. (2019). Communicating Auditory Impairments Using Electroacoustic Composition. Electronic workshops in computing. https://doi.org/10.14236/ewic/eva2019.63
140. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
141. Daley, D. C., & Douaihy, A. (2019). Understanding Substance Use Problems. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0002
142. Davies, D. (2023). Defining Alcoholism. Routledge eBooks. https://doi.org/10.4324/9781032616988-5
143. Dervaux, A. (2013). En quoi et comment le cannabis peut-il être toxique pour le cerveau ?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2013.09.004
144. Dervaux, A. (2018). [Cannabis use disorders and psychiatric comorbidities].. PubMed.
145. Diarra, E., Jedynak, C. P., & Verny, M. (2008). [Tremor in the elderly].. PubMed. https://doi.org/10.1684/pnv.2008.0139
146. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
147. Dilsaver, S. C., Halle, M. H., & Medico, V. J. D. (1991). Symptoms of major depression: acute effect of withdrawing antidepressants. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1991.tb05531.x
148. Ding, K., Gupta, P. K., & Diaz‐Arrastia, R. (2016). Epilepsy after Traumatic Brain Injury. CRC Press, Taylor and Francis Group eBooks.
149. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
150. Domínguez, L. N., Martin, P. R., Olea, A. M., Martínez, N. B., Sanjosé, G. U., González, M. M., & Tolosa-Delgado, A. (2016). Atypical Psychotic Symptoms in Lafora´s Disease: A Case Report.
151. Donghi, A. (2005). ALCANCE DE LA APLICACIÓN DEL MODELO DE REDUCCIÓN DE DAÑOS AL CAMPO ASISTENCIAL EN EL TRATAMIENTO DE LAS ADICCIONES. XII Jornadas de Investigación y Primer Encuentro de Investigadores en Psicología del Mercosur.
152. Donghi, A., Maidana, M., Vázquez, L. G., & Rodríguez, R. O. (2011). DIAGNÓSTICO DIFERENCIAL (NEUROSIS-PSICOSIS) DEL MODO DE TRATAMIENTO DEL DOLOR EN CONSUMIDORES DE PASTA BASE DE COCAÍNA (PACO). III Congreso Internacional de Investigación y Práctica Profesional en Psicología XVIII Jornadas de Investigación Séptimo Encuentro de Investigadores en Psicología del MERCOSUR.
153. Duperrouzel, J. C., Ross, J. M., Pacheco‐Colón, I., & González, R. (2020). Psychosocial. The Wiley Encyclopedia of Health Psychology. https://doi.org/10.1002/9781119057840.ch31
154. Durst, R., Teitelbaum, A., Katz, G., & Knobler, H. (1999). Withdrawal from clozapine: the "rebound phenomenon".. PubMed.
155. D’Souza, D. C. (2023). Cannabis, cannabinoids and psychosis: a balanced view. World Psychiatry. https://doi.org/10.1002/wps.21075
156. Edinoff, A. N., Sauce, E., Ochoa, C., Cross, J., Cogburn, M., Cornett, E. M., Kaye, A. M., Pham, A., & Kaye, A. D. (2021). Clozapine and Constipation: A Review of Clinical Considerations and Treatment Options. Psychiatry International. https://doi.org/10.3390/psychiatryint2030026
157. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
158. EKİCİ, A. Ş., Şahin, Ş. K., Elboğa, G., & Altındağ, A. (2020). Mania Induced by a Single Dose of Synthetic Cannabinoid. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0000000000000212
159. Engelmann, C. M., & Siert, L. (2007). [Cognitive disturbances following severe traumatic brain injury].. PubMed.
160. Erber, N. P., & Scherer, S. (1999). Sensory Loss and Communication Difficulties in the Elderly. Australasian Journal on Ageing. https://doi.org/10.1111/j.1741-6612.1999.tb00079.x
161. Escayola, E. N., Caballero, J. M. M.-Q., & Valencia, B. C. (2014). Valoración médico forense de muerte en custodia por delirium agitado. A propósito de un caso.
162. Esquiliano, G. R., Ramírez, I. M., Valdés, A. T., & Aguilar, C. A. T. (2004). Daño neurológico secundario a hipoxia isquemia perinatal. Archivos de neurociencias (México, D.F.).
163. Estroff, T. W., & Gold, M. S. (2022). Medical and Psychiatric Complications of Cocaine Abuse With Possible Points of Pharmacological Treatment. Routledge eBooks. https://doi.org/10.4324/9781003282822-6
164. Evren, C., & Dalbudak, E. (2009). Relationship of Personality Trait Impulsivity with Clinical Variables in Male Alcohol-Dependent Inpatients. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
165. Fachrudin, D. (2019). Episode Depresif Berat dengan Gejala Psikotik (Studi Kasus dalam Perspektif Psikologi dengan Pendekatan Teori Kognitif Beck). Tunas Medika Jurnal Kedokteran & Kesehatan.
166. Fama, J. M., & Wilhelm, S. (2010). Obsessions. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0616
167. Farne, H., Norris-Cervetto, E., & Warbrick‐Smith, J. (2015). Blackout. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198716228.003.0009
168. Farıdhosseını, F., & Zamani, A. (2012). A case report of somnambulism associated with olanzapine.. PubMed.
169. Fava, G. A., Benasi, G., & Cosci, F. (2017). The Potential Role of Iatrogenic Comorbidity in the Interaction between Pharmacotherapy and Psychotherapy in Anxiety Disorders. Verhaltenstherapie. https://doi.org/10.1159/000460826
170. Feinstein, A., Banwell, E., & Pavisian, B. (2015). What to make of cannabis and cognition in MS: In search of clarity amidst the haze. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458515607652
171. Ferrara, P. (2014). Child abuse and neglect: psychiatric and neuro-biological consequences. The Italian Journal of Pediatrics/Italian journal of pediatrics. https://doi.org/10.1186/1824-7288-40-s1-a32
172. Ferreira, S., Moutinho, L., & Diegues, P. (2014). Do copo meio cheio à mente vazia: o impacto do consumo do álcool no funcionamento cognitivo. Revista de Psicologia da Criança e do Adolescente.
173. Fiar, Z., Hroudov, J., & Raboch, J. (2012). Neurotransmission in Mood Disorders. InTech eBooks. https://doi.org/10.5772/31831
174. Fisher, R. S., Acevedo, C. A., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Forsgren, L., French, J. A., Glynn, M., Hesdorffer, D. C., Lee, B. I., Mathern, G. W., Moshé, S. L., Perucca, E., Scheffer, I. E., Tomson, T., Watanabe, M., & Wiebe, S. (2014). ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia. https://doi.org/10.1111/epi.12550
175. Fitzgerald, P. J., & Watson, B. O. (2018). Gamma oscillations as a biomarker for major depression: an emerging topic. Translational Psychiatry. https://doi.org/10.1038/s41398-018-0239-y
176. Fjældstad, A. W. (2018). Testing olfactory function and mapping the structural olfactory networks in the brain.. Research Portal Denmark.
177. Foo, Y.-C., Tam, C. L., Ehsan, S. D., & Cheah, J. (2012). Impacts of Drug Use on Memory. AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES.
178. Forcén, F. E. (2015). Akathisia: Is Restlessness a Primary Condition or an Adverse Drug Effect? Keep a Discerning Eye out for This Adverse Effect of Antipsychotics and Other Drugs. Current psychiatry.
179. Foroutan, H. R., Vadiee, I., Nabavizadeh, A., Rafiee, M., Imanieh, M. H., Asadipouya, A., & Pirastehfar, M. (2005). CIDP and Achalasia: Two manifestations of a Disease or Coincidental Association. Iranian journal of medical sciences.
180. Fox, C., Jimoh, F. O., & Cross, J. (2018). Intervention to prevent, delay or reduce frailty in community-living older adults..
181. Franken, I. H. A., & Wiers, R. W. (2013). [Motivational processes in addiction: the role of craving, salience and attention].. PubMed.
182. França, A. P., Takahashi, R. Ν., Cunha, R. A., & Prediger, R. D. (2018). Promises of Caffeine in Attention-Deficit/Hyperactivity Disorder: From Animal Models to Clinical Practice. Journal of Caffeine and Adenosine Research. https://doi.org/10.1089/caff.2018.0016
183. Frymark, T., Leech, H. M., Mullen, R., Schooling, T., Venediktov, R., & Wang, B. (2010). Evidence-Based Systematic Review (EBSR): Drug-Induced Hearing Loss— Aminoglycosides.
184. Gallagher, P., Ashton, C. H., Moore, P. B., & Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology. https://doi.org/10.1177/0269881105051541
185. Ganguly, J., Banerjee, S., Basu, P., Mukherjee, S., Singh, N., & Kumar, H. (2025). Teaching Video NeuroImage: String Hallucinations in Parkinson Disease. Neurology. https://doi.org/10.1212/wnl.0000000000213611
186. Garg, T., & Rawat, V. S. (2023). Trihexyphenidyl Use Disorder and Withdrawal Syndrome. Journal of Psychiatry Spectrum. https://doi.org/10.4103/jopsys.jopsys_12_23
187. Garrabé, J., & Cousin, F. (2012). Acute and transient psychotic disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0081
188. Garro, A., Bond, G. R., & Gilbert, D. L. (2007). Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clinical Toxicology. https://doi.org/10.1080/15563650600981178
189. Garrote, J. B., Casanova, T., Antón, R., Campos, A. R., Pérez, S. C., Sánchez, S. G., Garcia, G., Andrés, L. R., Garcia, M., Canga, C. N., Astorga, A. Á., & Gallego, H. D. L. R. (2016). How strange is everything. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1859
190. Gay, C. (2009). [Atypical bipolar disorders].. PubMed.
191. Gehricke, J., Loughlin, S. E., Whalen, C. K., Potkin, S. G., Fallon, J., Jamner, L. D., Belluzzi, J. D., & Leslie, F. M. (2007). Smoking to self-medicate attentional and emotional dysfunctions. Nicotine & Tobacco Research. https://doi.org/10.1080/14622200701685039
192. Geoffroy, P. A., Rolland, B., & Cottencin, O. (2012). Catatonia and Alcohol Withdrawal: A Complex and Underestimated Syndrome. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agr170
193. George, O., & Koob, G. F. (2017). Individual differences in the neuropsychopathology of addiction. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2017.19.3/gkoob
194. Gheorman, V., Dinescu, V. C., Criciotoiu, O., Stanca, D., Calborean, V., Mită, A., Miscoci, A., Daviţoiu, D. V., Băleanu, V. D., Nedelcuta, R.-M., Dinescu, S. N., Dijmărescu, A. L., Voiculescu, D., & Udriștoiu, I. (2019). Clinical and Biochemical Changes Induced by Alcohol at the Patients with Mental Illness. Revista de Chimie. https://doi.org/10.37358/rc.19.4.7138
195. Giménez, V. M. M., Mazzei, L., Sanz, R., & Manucha, W. (2022). Cannabinoids as Potential Molecules for Addiction Disorders. Current Protein and Peptide Science. https://doi.org/10.2174/1389203723666220510121031
196. Giulio, P. (2020). Dysfunctional sexual behaviors: definition, clinical contexts, neurobiological profiles and treatments. International Journal of Sexual and Reproductive Health Care. https://doi.org/10.17352/ijsrhc.000015
197. Glueck, B. (2017). Psychophysiological Correlates of Meditation: Eeg Changes During Meditation *. Routledge eBooks. https://doi.org/10.4324/9780203785843-56
198. Gnanavel, S. (2013). Quetiapine-induced manic episode: a paradox for contemplation. BMJ Case Reports. https://doi.org/10.1136/bcr-2013-201761
199. Goldfeder, S., Scott, R., & Briggs, J. P. (2023). Forensic Assessments of Alcohol, Cannabis and Methamphetamine Intoxication in Cases of Violent Offending.. PubMed.
200. Gonem, S. (2017). Constipation. CRC Press eBooks. https://doi.org/10.4324/9781315383798-18
201. González, R. M., Quesada, H. S., & Sancho, L. V. (2010). Episodio mixto secundario al uso de fluoxetina en una paciente con un transtorno afectivo bipolar no diagnosticado. Revista Médica de Costa Rica y Centroamérica.
202. Gopalan, R. T. (2016). Intellectual Disability. Advances in psychology, mental health, and behavioral studies (APMHBS) book series. https://doi.org/10.4018/978-1-5225-0089-6.ch001
203. Goyal, S., Ambekar, A., & Ray, R. (2014). Ketamine Dependence in an Anesthesiologist: An Occupational Hazard?. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.135395
204. Group, M. T., Mackway‐Jones, K., Marsden, J., & Windle, J. (2006). Discriminator Dictionary. https://doi.org/10.1002/9780470757321.oth3
205. Grover, S. (2017). Depressive Symptoms in Persons with Epilepsy: Methodological Issues. Journal of Neurosciences in Rural Practice. https://doi.org/10.4103/jnrp.jnrp_215_17
206. Gupta, D., & O’Hara, C. (2019). Aripiprazole Toxicity With a Biphasic Course of Somnolence. Pediatric Emergency Care. https://doi.org/10.1097/pec.0000000000001889
207. Gupta, N., Ojo, O., & Muruthettuwegama, K. (2013). Cannabinoid Hyper-emesis Syndrome: An Enigma. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.122241
208. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
209. Gusmão, C. M. D., Garcia, L. R., Jesuthasan, A., Muir, M., Paciorkowski, A. R., Mink, J. W., & Silveira‐Moriyama, L. (2020). <scp>Kinesigenic</scp> Triggers in Episodic Ataxia Type 1. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.13008
210. Gusmão, C. M. D., Maski, K., & Urion, D. K. (2014). Kleine-Levin Syndrome with Rapid Cycling - Case Report and Review of the Literature (P5.294). Neurology. https://doi.org/10.1212/wnl.82.10_supplement.p5.294
211. Gërguri, A., Maloku, A., Zeka, N., Vuçitërna, A., Bejiqi, R., & Retkoceri, R. (2015). EEG as Prognostic Argument in First Afebril Seizures. Anglisticum Journal. https://doi.org/10.0001/(aj).v4i8.1205
212. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
213. Hall, W. (2012). The mental health effects of cannabis use. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0068
214. Hall, W., & Degenhardt, L. (2010). Schizophrenia secondary to cannabis use. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511789977.012
215. Hamed, S. A. (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1372420
216. Hammeke, T. A., McQuillen, M. P., & Cohen, B. A. (1983). Musical hallucinations associated with acquired deafness.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.46.6.570
217. Hantson, P. (2004). Convulsions d'origine toxique. Réanimation. https://doi.org/10.1016/j.reaurg.2004.03.015
218. Harful, S., Snehal, V. T., Kamal, K., Vijay, K. S., Santosh, K. K., & Niran, N. (2021). Lacosamide Induced Hyperactivity in a Mental Retarded Child with Seizure Disorder: A Case Report. IP Indian Journal of Neurosciences.
219. Hartston, H. (2012). The Case for Compulsive Shopping as an Addiction. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2012.660110
220. Heekerens, J. B., Gross, J. J., Kreibig, S. D., Wingenfeld, K., & Röpke, S. (2023). The Temporal Dynamics of Dissociation: Protocol for an Ecological Momentary Assessment and Laboratory Study in a Transdiagnostic Sample. https://doi.org/10.31234/osf.io/aq63g
221. Hemmingsen, R., Kramp, P., & Rafaelsen, O. J. (1983). Organic cerebral reactions in alcoholism: psychobiological aspects of treatment.. PubMed.
222. Herreras, E. B., & Gutiérrez, G. M. (2008). Adicciones y funcionamiento ejecutivo. Polibea.
223. Herreras, E. B., & Gutiérrez, G. M. (2008). Adicciones y funcionamiento ejecutivo. Psicología y Psicopedagogía.
224. Hertz, L., Song, D., Li, B., Du, T., Xu, J., Gu, L., Chen, Y., & Liang, P. (2014). Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders. Journal of Signal Transduction. https://doi.org/10.1155/2014/593934
225. Heylens, G., Roosens, E., Mulier, J. P., & Fruyt, J. D. (2017). [The use of dexmedetomidine in extreme agitation].. PubMed.
226. Hj, A., Barrucand, D., & Auzépy, P. (1993). [Alcohol withdrawal syndrome and delirium tremens. Their treatment].. PubMed.
227. Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2024). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01880-2
228. Hollister, L. E. (1971). Current Research on Marijuana. Journal of Social Issues. https://doi.org/10.1111/j.1540-4560.1971.tb00666.x
229. Hughes, J. R. (1999). Comorbidity and smoking. Nicotine & Tobacco Research. https://doi.org/10.1080/14622299050011981
230. Huis, K. (2014). Suvremeno liječenje paničnog poremećaja.
231. Hyytiä, P. (2015). [The effect of abused drugs on the developing brain during childhood and adolescence].. PubMed.
232. Häfner, H. (2005). Psychosis and cannabis. Archives of Clinical Psychiatry (São Paulo). https://doi.org/10.1590/s0101-60832005000200001
233. Ibáñez, C., Benavides, D., & Valle, D. (2019). Síndrome de hiperémesis por cannabinoides: caso clínico. Revista Hospital Clínico Universidad de Chile. https://doi.org/10.5354/2735-7996.2019.70048
234. Ilbeigi, M. S., Davidson, M., & Yarmush, J. (1998). An Unexpected Arousal Effect of Etomidate in a Patient on High-dose Steroids . Anesthesiology. https://doi.org/10.1097/00000542-199812000-00045
235. Ingrassia, G. F. (2012). HISTORICAL EVOLUTION OF MEDICAL KNOWLEDGE IN THE FIELD OF VEGETATIVE STATE.
236. Inguscio, L., Caponnetto, P., Valeri, S., Maglia, M., Polosa, R., Lai, C., & Mazzoni, G. (2021). Smartphone addiction through age and gender during Italian lockdown for COVID-19. Proceedings of The 3rd International Electronic Conference on Environmental Research and Public Health —Public Health Issues in the Context of the COVID-19 Pandemic. https://doi.org/10.3390/ecerph-3-09027
237. Ishii, K., Tamaoka, A., Otsuka, F., Iwasaki, N., Shin, K., Matsui, A., Endo, G., Kumagai, Y., Ishii, T., Shoji, S., Ogata, T., ISHIZAKI, M., Doi, M., & Shimojo, N. (2004). Diphenylarsinic acid poisoning from chemical weapons in Kamisu, Japan. Annals of Neurology. https://doi.org/10.1002/ana.20290
238. IuIu, I., Vl, R., & Tv, S. (2012). [Early resorptive effects of highly toxic alkylating substances].. PubMed.
239. Jacques, J., Zombek, S., Guillain, C., & Duez, P. (2004). [Cannabis: experts agree more than they admit].. PubMed.
240. Jaffee, M. S., Broshek, D. K., & Svingos, A. M. (2023). What Is a Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190630119.003.0001
241. Jain, N., Himanshu, D., Verma, S., & Parihar, A. (2013). Methanol poisoning: characteristic MRI findings. Annals of Saudi Medicine. https://doi.org/10.5144/0256-4947.2012.26.5.1114
242. Jang, W. I., Kim, Y. S., Kim, D. W., & Lee, B. D. (2010). A Case of Bilateral Sudden Sensorineural Hearing Loss Occurring after Taking the Aspirin. Journal of Clinical Otolaryngology Head and Neck Surgery. https://doi.org/10.35420/jcohns.2010.21.1.67
243. Janković, D., Tanaka, R., Sasaki, K., Miyatani, K., Chemate, S., Nakipuria, M., Tamura, T., Komatsu, F., Yamada, Y., & Kato, Y. (2023). Contrast-Induced Encephalopathy after Endovascular Treatment: Two Case Reports. Asian Journal of Neurosurgery. https://doi.org/10.1055/s-0043-1776991
244. Jargin, S. V. (2019). Some aspects of tobacco smoking in the context of alcohol drinking, hangover and mental health problems. International Journal of Psychiatry Research. https://doi.org/10.33545/26648962.2019.v1.i2a.10
245. Jaspal, H., Neupane, D., & Madhusoodanan, S. (2019). Coprophagia in an older adult with Schizophrenia- A case report and brief review. Medical Case reports and Reviews. https://doi.org/10.15761/mcrr.1000135
246. Jl, T. (1999). [Symptomatic and concurrent depressions].. PubMed.
247. Jm, V. G., Hj, G., Rj, V., & Af, C. (1998). [Cognitive and psychotic effects after cessation of chronic cannabis use].. PubMed.
248. Jockers‐Scherübl, M. C. (2006). [Schizophrenia and cannabis consumption: epidemiology and clinical symptoms]..
249. Jones, R. T., Benowitz, N. L., & Herning, R. I. (1981). Clinical Relevance of Cannabis Tolerance and Dependence. The Journal of Clinical Pharmacology. https://doi.org/10.1002/j.1552-4604.1981.tb02589.x
250. Jonge, M. E. A.-D., Portier, C., & Franssen, E. J. F. (2007). [Automutilation after consumption of hallucinogenic mushrooms].. PubMed.
251. Joseph, A. B., & Wroblewski, B. (1993). Potentially toxic serum concentrations of desipramine after discontinuation of valproic acid. Brain Injury. https://doi.org/10.3109/02699059309029690
252. Joseph, C., Ojo, O., Popoola, O., Azizi, H., Khan, T., Pramanik, O., Kahn, A., Chaudhry, S. R., Rimawi, D., Singh, M., Mallick, A., Paul, S., Ojimba, C., & Jolayemi, A. (2018). A case of brief psychosis upon cannabis withdrawal. MOJ Addiction Medicine & Therapy. https://doi.org/10.15406/mojamt.2018.05.00135
253. Joshi, A., Shah, P. S., & Khanna, H. (2023). DIAGNOSTIC CHALLENGES OF HYPERSOMNIA IN AN INDIAN CHILD: A CASE REPORT. Indian Journal Of Applied Research. https://doi.org/10.36106/ijar/5301041
254. Joshi, S., & Goodkin, H. P. (2020). The Need to Intervene Before Time Point 2: Evidence From Clinical and Animal Data That Status Epilepticus Damages the Brain. Journal of Clinical Neurophysiology. https://doi.org/10.1097/wnp.0000000000000711
255. Jovanović, J., Lazaridis, K., & Stefanović, V. (2006). THEORETICAL APPROACHES TO PROBLEM OF OCCUPATIONAL STRESS. Acta Facultatis Medicae Naissensis.
256. Kalivas, P. W. (2003). Development and Expression of Behavioral Sensitization. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_9
257. Kalivas, P. W., Toda, S., Bowers, M. S., Baker, D. L., & Ghasemzadeh, M. B. (2003). The Temporal Sequence of Changes in Gene Expression by Drugs of Abuse. Humana Press eBooks. https://doi.org/10.1385/1-59259-358-5:03
258. Kalla, C. (2020). [SWITCH TO MANIC EPISODE WITH MIXED FEATURES IN DEPRESSIVE SOLDIER UNDER ANTIDEPRESSANT TREATMENT].. PubMed.
259. Kambuzuma, P., & Marais, B. (2025). A case of clozapine-induced stuttering in a HIV-positive individual. South African Journal of Psychiatry. https://doi.org/10.4102/sajpsychiatry.v31i0.2462
260. Kanyengo, C. W. (2009). Zambia: The challenge of informing blind and deaf clients.
261. Karadima, D., Tsopelas, C., Dimitraka, M., Ntounas, P., Gatos-Gatopoulos, A., & Charalampos, T. (2016). Use of cannabis components in the treatment of mental disorders. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2036
262. Karila, L., Roux, P., Rolland, B., Benyamina, A., Reynaud, M., Aubin, H., & Lançon, C. (2014). Acute and Long-Term Effects of Cannabis Use: A Review. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990620
263. Katiri, R., Hall, D. A., & Kitterick, P. T. (2020). Developing an International Core Outcome Set for SSD Interventions. The Hearing Journal. https://doi.org/10.1097/01.hj.0000661612.83232.57
264. Kašpárek, T., Dreisig, M., & Barteček, R. (2014). Alkoholový odvykací stav a delirium - od patofyziologie k léčbě. Česká a slovenská neurologie a neurochirurgie.
265. Keary, C. J., Nejad, S. H., Rasimas, J. J., & Stern, T. A. (2013). Intoxications Associated With Agitation, Tachycardia, Hypertension, and Fever: Differential Diagnosis, Evaluation, and Management. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.12f01459
266. Kemp, S. F., & Lockey, R. F. (2010). Pathophysiology and Organ Damage in Anaphylaxis. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-951-2_3
267. Kennedy, D. B., & Savard, D. M. (2017). Delayed In-Custody Death Involving Excited Delirium. Journal of Correctional Health Care. https://doi.org/10.1177/1078345817726085
268. Khalafian, A., Dukes, C., & Tucker, P. (2015). Consultation Dilemma Catatonia in a Patient with Prior TBI: MentaI or Medical Disorder?. PubMed.
269. Killebrew, K. W., Moser, H. R., Grant, A., Sponheim, S. R., Anker, J. J., & Schallmo, M.-P. (2023). The effect of tobacco use on performance in a structure-from-motion task among patients with psychotic psychopathology.. Journal of Vision. https://doi.org/10.1167/jov.23.9.5397
270. Kim, D.-H., Kang, M. S., Song, H. S., & Hwang, J. H. (2019). Synergistic Effect of Wild Ginseng Complex Pharmacopuncture Combined with Korean Medicine Automobile Insurance Treatment on Two Obese Inpatients with Systemic Symptoms: Case Series. Korean Journal of Acupuncture. https://doi.org/10.14406/acu.2019.004
271. Kintz, P., Villain, M., & Cirimele, V. (2008). Chemical Abuse in the Elderly: Evidence From Hair Analysis. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0b013e31816bac44
272. Kintz, P., Villain, M., Cirimele, V., Goullé, J., & Ludes, B. (2002). [Crime under the influence of psychoactive drugs: the problem of the duration of detection].. PubMed.
273. Klaassen, T. (2021). Novel strategies to address disrupted sensing and signalling of satiety. https://doi.org/10.26481/dis.20210903tk
274. Klega, A. E., & Keehbauch, J. (2018). Stimulant and Designer Drug Use: Primary Care Management.. PubMed.
275. Klott, J., & Jongsma, A. E. (2006). The Co-Occurring Disorders Treatment Planner.
276. Knaap, M. S. V. D., Depienne, C., Sedel, F., & Abbink, T. E. M. (2015). CLCN2-Related Leukoencephalopathy.
277. Knight, E., & McIntyre, A. (2012). Pharmacy medications and driving: delivering key information to ageing drivers.
278. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
279. Kobayashi, T., Hayakawa, S., Matsuda, M., Tsuchida, H., Haga, H., Tani, N., & Fukui, K. (1999). [Mental and physical symptoms in alcoholics after alcohol withdrawal--comparing with involutional melancholia patients].. PubMed.
280. Kokaçya, M. H., Çöpoğlu, Ü. S., Şahpolat, M., & Arı, M. (2015). A Case of Cannabis Use-Associated Psychotic Disorder Accompanied by Autoscopic Phenomena. Addicta The Turkish Journal on Addictions. https://doi.org/10.15805/addicta.2015.2.1.061e
281. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4.473
282. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4_part_2.473
283. Koob, G. F. (2013). Neurocircuitry of Addiction: A brain reward deficit, stress surfeit and executive function disorder. Suchttherapie. https://doi.org/10.1055/s-0033-1351398
284. Koob, G. F. (2020). Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.120.000083
285. Koshy, R., & Sudha, P. (2011). Nonconvulsive status epilepticus: An unusual cause of postoperative unresponsiveness following general anaesthesia. Indian Journal of Anaesthesia. https://doi.org/10.4103/0019-5049.79901
286. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
287. Kotlęga, D., Peda, B., Gołąb-Janowska, M., & Nowacki, P. (2017). Delayed neurological sequelae in carbon monoxide poisoning – a case report and present state of knowledge. Pomeranian Journal of Life Sciences. https://doi.org/10.21164/pomjlifesci.299
288. Kumar, S., & Singh, A. K. (2019). A Clinical Study to evaluate the effect of Dushivishari Ajay Ghrita in Dushivisha Janya Lakshana. Journal of Ayurveda and Integrated Medical Sciences. https://doi.org/10.21760/jaims.4.2.2
289. Lacomblez, L. (1998). [Drug therapy strategies in Alzheimer's disease].. PubMed.
290. Landa, E., Vigandt, E., Andreev, A., Malyshev, Y., & Sahni, S. (2019). Cannabis-induced Acute Coronary Syndrome: A Coincidence or Not?. Cureus. https://doi.org/10.7759/cureus.5696
291. Lane, H., Su, K., & Chang, W. (1999). Seizures After Discontinuation of Low-Dose Lorazepam From Originally Seizure-Free Clozapine Regimen. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v60n0611b
292. Lanièpce, A., Cabé, N., André, C., Bertran, F., Boudehent, C., Lahbairi, N., Maillard, A., Mary, A., Segobin, S., Vabret, F., Rauchs, G., & Pitel, A. (2020). The effect of alcohol withdrawal syndrome severity on sleep, brain and cognition. Brain Communications. https://doi.org/10.1093/braincomms/fcaa123
293. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
294. Lee, K., Bahk, W., Yoon, B.-H., Jon, D., Lee, S.-Y., Kim, M.-D., Nam, B., & Song, M. (2018). T116. CAFFEINE-INDUCED PSYCHIATRIC MANIFESTATIONS. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sby016.392
295. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
296. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
297. Lerner, A. G., Goodman, C., Bor, O., & Lev‐Ran, S. (2014). Synthetic Cannabis Substances (SPS) Use and Hallucinogen Persisting Perception Disorder (HPPD): Two Case Reports.. PubMed.
298. LEÓN-CARRIÓN, M. D. R. D. M. J. (2006). Low-level responsive states. Taylor & Francis eBooks. https://doi.org/10.4324/9780203965238-15
299. Lheureux, P., & Penaloza, A. (2004). [Ototoxicity-related dysequilibrium].. PubMed.
300. Ligier, F., & Kabuth, B. (2016). Between Neurology and Psychiatry, a Difficult Preliminary Diagnosis of Kleine-levin Syndrome: Case-report of a Young Girl. Journal of Child and Adolescent Behaviour. https://doi.org/10.4172/2375-4494.1000274
301. Lim, H., Kwon, Y.-J., Lee, J.-E., & Cho, S. (2013). Reconsideration of Psychasthenia- Two Cases. Journal of Oriental Neuropsychiatry. https://doi.org/10.7231/jon.2013.24.3.245
302. Linde, C. (2014). Panic disorder : what it is and how to treat it. Mental Health Matters.
303. Lipar, L., Vovk, P., Weiss, T., & Kšela, J. (2018). Swallow Syncope After Whiplash Neck Injury. The Heart Surgery Forum. https://doi.org/10.1532/hsf.1933
304. Liu, G., Slater, N., & Perkins, A. (2017). Epilepsy: Treatment Options.. PubMed.
305. Llcms, L. C., Martins, P. R. C., Loures, É. N., Vitalino, A. R., Lotufo, C. C., & Onady, S. Y. (2017). ATAQUE ISQUÊMICO TRANSITÓRIO E ESTADO DE MAL EPILÉPTICO COMO MANIFESTAÇÕES DE INTOXICAÇÃO AGUDA E ABSTINÊNCIA POR CRACK E COCAÍNA.
306. Lobato, E. F. (2013). Persistent hiccup treated by hypnosis. Revista Médica de Minas Gerais. https://doi.org/10.5935/2238-3182.20130040
307. Loga, S., Loga-Zec, S., & Spremo, M. (2010). Cannabis and psychiatric disorders.. PubMed.
308. Logan, B. K., & Couper, F. J. (2003). 3,4-Methylenedioxymethamphetamine - Effects on Human Performance and Behavior.. PubMed.
309. Loganovskaja, T., & Loganovsky, K. (2013). 1319 – Psychiatric legacy of chernobyl: fukushima projections. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)76373-9
310. Lopes, R., Azevedo, J., Curral, R., Esteves, M., & Coelho, R. (2011). A case clozapine induced palilalia. European Psychiatry. https://doi.org/10.1016/s0924-9338(11)72931-5
311. Lucas, C., Galettis, P., & Schneider, J. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.13710
312. Lyvers, M. (1998). Drug addiction as a physical disease: The role of physical dependence and other chronic drug-induced neurophysiological changes in compulsive drug self-administration.. Experimental and Clinical Psychopharmacology. https://doi.org/10.1037//1064-1297.6.1.107
313. Lyvers, M. (1998). Drug addiction as a physical disease: The role of physical dependence and other chronic drug-induced neurophysiological changes in compulsive drug self-administration.. Experimental and Clinical Psychopharmacology. https://doi.org/10.1037/1064-1297.6.1.107
314. López, A. M., Martínez, L. R. D., & Moreno, J. (2012). Uso de marcadores bioquímicos para valoración de riesgo de crisis convulsivas en el síndrome de supresión etílica. Salud Mental.
315. M.E., B., VergelHernández, J., C.A., H., C.S., M., Ospina-Otálvaro, S., J.D., S., P.M., A., J.J., A., Basic, A. C. N. S. R. T. O., & Psychiatry, S. O. M. R. T. O. (2021). Supplementary Material for: Neuropsychiatric Aspects in a Patient Diagnosed with Frontotemporal Dementia: Clinical Case of Low Incidence and Prevalence Disease in Colombia. Figshare. https://doi.org/10.6084/m9.figshare.14932008
316. Macneil, C., Hasty, M., Conus, P., Berk, M., & Scott, J. (2009). Social rhythm regulation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511757389.008
317. Madrid, P. A., Grant, R., Reilly, M. J., & Redlener, N. B. (2006). Challenges in Meeting Immediate Emotional Needs: Short-term Impact of a Major Disaster on Children's Mental Health: Building Resiliency in the Aftermath of Hurricane Katrina. PEDIATRICS. https://doi.org/10.1542/peds.2006-0099u
318. Mahadevan, J., D’cruz, M., Chand, P., & Murthy, P. (2019). An interesting presentation of psychotic catatonia in an elderly patient with alcohol dependence. Journal of Geriatric Mental Health. https://doi.org/10.4103/jgmh.jgmh_33_19
319. Mahadewi, N. P., Marita, A., & Ariani, N. P. (2018). Gangguan mental organik pada epilepsi. Medicina Journal. https://doi.org/10.15562/medicina.v49i2.248
320. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
321. Malenfant, M., Tremblay, S., Laurin, D., & Lefèbvre, J. (2008). L'utilisation du citalopram pour traiter l'agitation et les symptômes psychotiques chez les patients souffrant de démence.
322. Malik, H. U.-R., & Kumar, K. (2012). Serotonin Syndrome with Escitolapram and Concomitant Use of Cocaine: A Case Report. Clinical Medicine Insights Case Reports. https://doi.org/10.4137/ccrep.s9540
323. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
324. Marchesi, C., Tonna, M., & Maggini, C. (2008). Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970701459828
325. Marcus, A., Bahro, M., Sartoris, J., & Schmidt, M. (1993). Acute Exogenic Psychosis Following Oral Ingestion of 2mg Lormetazepam in an Eleven-Year-Old Boy. Pharmacopsychiatry. https://doi.org/10.1055/s-2007-1014352
326. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
327. Marković, H., Nikolac, N., Tripković, M., Haluga-Golubović, I., & Čustović, Z. (2012). Connection between Addictive Behavior and Investing on the Stock Market in Croatia.
328. Martin, C. M. (2007). &lt;b&gt;It's Nothing to Laugh About: Understanding Disorders of Emotional Expression&lt;/b&gt;. The Consultant Pharmacist. https://doi.org/10.4140/tcp.n.2007.732
329. Mauri, M. C. (2016). Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100011
330. McFerran, D., & Baguley, D. (2007). Acoustic shock. The Journal of Laryngology & Otology. https://doi.org/10.1017/s0022215107006111
331. McIntyre, R. S., & Calabrese, J. R. (2019). Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2019.1636017
332. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
333. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
334. Mehta, U. M., Kumar, C. N., Venkatasubramanian, G., & Thirthalli, J. (2013). Multimodal Sensory Distortions in Postpartum Exacerbation of Schizophrenia. Clinical Schizophrenia & Related Psychoses. https://doi.org/10.3371/csrp.meku.112013
335. Mejía-Rodríguez, D., González, L. E. M., & Mejía, M. C. B. (2020). Intoxicaciones por bupropión: presentación de caso. Revista Médicas UIS. https://doi.org/10.18273/revmed.v33n2-2020014
336. Melo-Dias, C., Apóstolo, J., & Cardoso, D. (2014). Effectiveness of progressive muscle relaxation training for adults diagnosed with schizophrenia: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/jbisrir-2014-1639
337. Mercês, T. M. D. (2019). Controle hidroeletrolítico e respostas cardiovasculares à injeção central de angII, carbacol e hiperosmolaridade plasmática em ratos com epilepsia induzida por pilocarpina.
338. MH, O., & Aksoy, İ. (2018). Use of Electroconvulsive Therapy (ECT) in Hysterical Catatonia: Case Reports of Two Women, One Young and One Elderly. JOURNAL OF CASE REPORTS AND STUDIES. https://doi.org/10.15744/2348-9820.6.306
339. Michel, J., Gisselbaek, A., Gauthey, L., & Zelger, G. L. (1993). [Non-compliant drug taking in elderly subjects].. PubMed.
340. Miller, M. W., Marx, B. P., & Keane, T. M. (2010). Posttraumatic Stress Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0699
341. MINEI, S., Kainuma, M., Sakamoto, H., Tamaki, N., TOMORI, H., CHOLSONG, Y., Nakahara, Y., & FURUSSYO, N. (2019). Consideration of a New Category of Patients for Whom Ryokeijutsukanto is Effective at a Different Stage Then was Previously Reported. Kampo Medicine. https://doi.org/10.3937/kampomed.70.141
342. Mirawati, D. K. (2018). Managing antiepileptic drug, Starting, Changing and Stopping AED’s.
343. Miyasato, K. (2013). [Psychiatric and psychological features of nicotine dependence].. PubMed.
344. Miyata, H., Kono, J., & Yanagita, T. (2005). Clinical features of nicotine dependence.
345. Mocanu, C., Cernea, D., Enache, M., & Deca, A. G. (2009). [General anesthesia in ophthalmology].. PubMed.
346. Mohedano, C. R., Espárrago‐Llorca, G., & Expósito, L. C. (2011). Comorbilidad psiquiátrica en la dependencia alcohólica (II): Alucinosis alcohólica, celotipia y otros trastornos.
347. Molero‐Chamizo, A. (2005). 3,4-metilenodioximetanfetamina (‘éxtasis’): efectos emocionales y cognitivos a largo plazo y depleción serotoninérgica. Revista de Neurología. https://doi.org/10.33588/rn.4102.2004547
348. Mollasadeghi, A., Mehrparvar, A. H., Atighechi, S., Davari, M. H., Shokouh, P., Mostaghaci, M., & Bahaloo, M. (2013). Sensorineural Hearing Loss after Magnetic Resonance Imaging. Case Reports in Radiology. https://doi.org/10.1155/2013/510258
349. Mondragón, A. G., Izquierdo, L. B., Múgica, F. A., & Ayerdi, I. Q. (2015). Leucoencefalopatía Hipóxica Tardía tras Autointoxicación: del Abordaje Psiquiátrico al Neurológico. Revista de la Asociación Española de Neuropsiquiatría. https://doi.org/10.4321/s0211-57352015000100011
350. Monti, M. M., Laureys, S., & Owen, A. M. (2010). The vegetative state. BMJ. https://doi.org/10.1136/bmj.c3765
351. Moore, B. A., Bowden‐Jones, H., Budney, A. J., & Vandrey, R. G. (2008). Treatment of cannabis dependence. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544392.024
352. Moorthi, K., Pertin, S., & Radhika, P. (2023). Homoeopathy for obsessive-compulsive disorder: A case report. Indian Journal of Research in Homoeopathy. https://doi.org/10.53945/2320-7094.1117
353. Morales, D. O. (2019). Muerte encefálica en pediatría..
354. Morales, N. N., Gómez‐Revuelta, M., Hernández, B., Zufiaurre, M. L., Itoiz, A. A., Olivares, O. P., González, G. M., Martin, M., Arenaza, J. G., & Arrillaga, A. G. P. (2017). Benzodiazepines abstinence syndrome with psychotic symptoms: Case report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.568
355. Morylowska-Topolska, J., Ziemiński, R., Molas, A., Gajewski, J., Flis, M., Stelmach, E., & Karakuła‐Juchnowicz, H. (2016). Schizophrenia and anorexia nervosa – reciprocal relationships. A literature review. Psychiatria Polska. https://doi.org/10.12740/pp/onlinefirst/63514
356. Mosley, M., Macdonald, R. L., Provencio, J. J., Simard, J. M., & James, R. F. (2015). Cognitive Dysfunction and Neuroinflammation After an aSAH. MD Conference Express. https://doi.org/10.1177/1559897715578121
357. Mukim, M., Devi, S. L., Sharma, P., Joshef, M. R., Nagar, J. C., & Ahmad, N. (2019). ANESTHESIA AND ITS APPPLICATION. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2019.6.4.5
358. Murti, A. S., & Sudaryanto, S. A. (2014). Asuhan Keperawatan Pada Tn. M Dengan Gangguan Sistem Persarafan: Stroke Non Hemoragik Di Ruang Anggrek Rumah Sakit Umum Daerah Pandan Arang Boyolali.
359. Mut, E. A., Pălădoiu, C., & Stănescu, M. (2021). Somatoform and conversion disorders as psychological defences. Journal of Educational Sciences & Psychology. https://doi.org/10.51865/jesp.2021.1.19
360. Méndez, A. V., Silva, P. L. N. D., Gonçalves, L. G. V., Chaves, S. C. D. S., Veiga, R. M., Mendez, A. E. R., Camilo, M. V. L., Mattos, L. C. D. A. N., Filho, M. R. S., Silva, R. D. G. D., Lima, G. F., Ferreira, C. S., & Santos, L. G. D. S. (2023). NEURONAL DAMAGE IN STATE EPILEPTICUS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593752318094
361. Méndez-Sánchez, F., Guisado, J. A., Palacios, R. D., & Teva, I. (2011). [Intracranial sinus thrombosis secondary to the consumption of inhaled speed].. PubMed.
362. Mırsal, H., Yaluğ, İ., Tan, D., Stern, T. A., Kalyoncu, A., Pektaş, Ö., Erdoğan, G., & Beyazyürek, M. (2005). Brief Report. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.v07n0505
363. Na, I., & Volel, B. A. (2002). [Clinical aspects of "folie du doute"].. PubMed.
364. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
365. Nakata, C., Nara, K., Kinoshita, F., Kikuchi, K., & Asai, M. (2015). [Alcohol withdrawal syndrome showing various progress: A case report].. PubMed.
366. Nakazawa, T. (1999). [Dependence and obsession].. PubMed.
367. Nandini., Yashaswini., C., & Harsha. (2021). Cannabis: Joints of Mental Illness. International Journal of Pharmaceutical Sciences Review and Research. https://doi.org/10.47583/ijpsrr.2021.v71i02.010
368. Nehretskii, S. (2023). Interdisciplinary Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Study of Abuse of Psychoactive Substances. SSP Modern Pharmacy and Medicine. https://doi.org/10.53933/sspmpm.v3i1.85
369. Nelson, J. D., & Chouinard, G. (1999). Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.. PubMed.
370. Neto, L. C. D. S., Miranda, G. A., Cunha, L. L. G. D., Canto, B. E. S., Strufaldi, V. P., Tetti, M. F., Akerman, M., & Matos, L. L. D. (2013). Consequências individuais e socioeconômicas da síndrome da apneia obstrutiva do sono. ABCS Health Sciences. https://doi.org/10.7322/abcshs.v38i1.6
371. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
372. Neven, A., & Blom, J. D. (2014). [Synesthesias in the context of hallucinogen-induced persistent perception disorder following the use of lsd].. PubMed.
373. Nguyen, D. C., Timmer, T. K., Davison, B. C., & McGrane, I. R. (2017). Possible <i>Garcinia cambogia</i>-Induced Mania With Psychosis: A Case Report. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190017734728
374. Niesink, R. J., & Laar, M. V. (2013). Does Cannabidiol Protect Against Adverse Psychological Effects of THC?. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2013.00130
375. Noël, X., Bechara, A., Brevers, D., Verbanck, P., & Campanella, S. (2010). Alcoholism and the Loss of Willpower. Journal of Psychophysiology. https://doi.org/10.1027/0269-8803/a000037
376. Nutt, D., & Nestor, L. J. (2018). Key elements of addiction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0003
377. Ojimba, C., Isidahome, E. E., Odenigbo, N., Umudi, O. D., & Olayinka, O. (2019). Catatonia in major depressive disorder: diagnostic dilemma. A case report. Journal of Psychology & Clinical Psychiatry. https://doi.org/10.15406/jpcpy.2019.10.00651
378. Oliveira, S., Canha, J., & Pereira, S. P. (2013). 2362 – Is it a prodrome of psychosis? Or is it naanxious disorder? A case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77202-x
379. Olowoyo, P., Oguntoye, O., Akinbote, J. A., & Akinyemi, M. O. R. (2018). Recurrent Prolonged Epileptic Fugue State Misdiagnosed as Psychosis? Tale of a Middle-Aged Female Nigerian African. International Journal of Innovative Research in Medical Science. https://doi.org/10.23958/ijirms/vol02-i09/04
380. Omar, R. (2016). Mental Disorder or Untreated Pneumonia. Journal of Forensic Biomechanics. https://doi.org/10.4172/2090-2697.1000127
381. Onda, K., Yukawa, T., Sakaue, M., Tsuboya, R., Inoue, E., & Someya, T. (2021). Withdrawal from long‐term use of caffeinated drinks can cause schizophrenia‐like symptoms: A case report. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13199
382. Oomen, P. P., Hell, H. H. V., & Bossong, M. G. (2018). The acute effects of cannabis on human executive function. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0000000000000426
383. Oscar‐Berman, M., & Bowirrat, A. (2005). Genetic influences in emotional dysfunction and alcoholism-related brain damage.. PubMed.
384. Osterman, J. E., Erdos, B. Z., Oldham, M., & Ivkovic, A. (2010). Antidepressant Treatments in PTSD. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-435-7_7
385. O’Connor, F. G., & Levine, B. D. (2015). Syncope in Athletes of Cardiac Origin. Current Sports Medicine Reports. https://doi.org/10.1097/01.csmr.0000465136.70746.5b
386. Padmos, R. C. (2009). Inflammatory Monocytes in Bipolar Disorder and Related Endocrine Autoimmune Diseases.
387. Page, R. D. (1983). Cerebral dysfunction associated with alcohol consumption.. PubMed.
388. Page, R. M. (2014). Substance Abuse and Adolescent Psychological Distress. The Wiley Blackwell Encyclopedia of Health, Illness, Behavior, and Society. https://doi.org/10.1002/9781118410868.wbehibs433
389. Paik, A., Oh, D., & Kim, D. (2014). A Case of Withdrawal Psychosis from Internet Addiction Disorder. Psychiatry Investigation. https://doi.org/10.4306/pi.2014.11.2.207
390. Pal, H., Kumar, R., Bhushan, S., & Berry, N. (2005). Psychiatric co-morbidity associated with pheniramine abuse and dependence. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.46079
391. Palijan, T. Ž., Kovačević, D., & Turcinović, M. K. (2007). Psychodynamic Characteristics of Ego in Alcoholic Offenders and Non-Offenders. Alcoholism Clinical and Experimental Research.
392. Pallesen, S., Olsen, O. K., Eide, E. M., Nortvedt, B., Grønli, J., Larøi, F., Nordmo, M., & Glomlien, F. E. (2018). Sleep deprivation and hallucinations. A qualitative study of military personnel. Military Psychology. https://doi.org/10.1080/08995605.2018.1478561
393. Pang, N. T. P., & Masiran, R. (2020). Mood disorder induced by prednisolone – an easily overlooked complication. Current Problems of Psychiatry. https://doi.org/10.2478/cpp-2020-0012
394. Papuc, I., LĂCĂTUŞ, R., Timen, A. M., Coşa, L., & Purdoiu, R. C. (2007). CANINE ANXIETY SINDROME BY DOG - OWNER SEPARATION TREATMENT. Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca Veterinary Medicine. https://doi.org/10.15835/buasvmcn-vm:64:1-2:2397
395. Pareja, J. A., Cuadrado, M. L., García‐Morales, I., Gil‐Nagel, A., & Franch, O. (2008). Hypnagogic Behavior Disorder: Complex Motor Behaviors During Wake–Sleep Transitions in 2 Young Children. Journal of Child Neurology. https://doi.org/10.1177/0883073808314964
396. Parker, R. S. (2012). Chronic Posttraumatic Disorders of Consciousness. CRC Press eBooks. https://doi.org/10.1201/b10562-14
397. Partinen, M., Huutoniemi, A., Kajaste, S., Lagerstedt, R., Markkula, J., Mäkinen, E., Paakkari, I., Partonen, T., Polo, P., Saarenpää‐Heikkilä, O., Seppälä, M., Kukkonen-Harjula, K., & Tuunainen, A. (2016). [Update on Current Care Guideline: Insomnia].. PubMed.
398. Passie, T., Emrich, H. M., Karst, M., Brandt, S. D., & Halpern, J. H. (2012). Mitigation of post‐traumatic stress symptoms by <i>Cannabis</i> resin: A review of the clinical and neurobiological evidence. Drug Testing and Analysis. https://doi.org/10.1002/dta.1377
399. Patricia, G. C. C., AAngela, G.-M., & Marina, R.-A. (2017). Diagnostic and therapeutical challenges of late-onset psychosis.. Journal of Psychology and Cognition. https://doi.org/10.35841/psychology-cognition.2.4.218-220
400. Paw, H., & Shulman, R. (2014). Management of status epilepticus. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781316182673.042
401. Pearlson, G. D. (2020). Psychology + human behavior. Weed Science. https://doi.org/10.1016/b978-0-12-818174-4.00006-9
402. Pechnick, R. N., Cunningham, K. A., & Danovitch, I. (2014). Hallucinogen-Related Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg51
403. Pendergraft, W. F., Herlitz, L., Thornley‐Brown, D., Rosner, M. H., & Niles, J. L. (2014). Nephrotoxic Effects of Common and Emerging Drugs of Abuse. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.00360114
404. Pereira, S. M. P., Guimarães, S. K. G., Marques, A., & Borges, S. (2008). Electroconvulsivotherapy in the elderly, indications, risks and side-effects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2008.01.611
405. Perera-Diltz, D. (2015). Cannabis Use Disorder. https://doi.org/10.63134/refd7106
406. Pergolizzi, J. V., LeQuang, J. A., & Bisney, J. (2018). Cannabinoid Hyperemesis. Medical Cannabis and Cannabinoids. https://doi.org/10.1159/000494992
407. Petit, J., & Sansone, R. A. (2011). A Case of Interdose Discontinuation Symptoms With Venlafaxine Extended Release. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01140
408. Petrescu, B., Vasile, D., Vasiliu, O., Mangalagiu, A., & Bădic, M. A. (2017). The Psychophysiological Effects of the Chemical Terrorist Attacks – the Neurotoxic Agent: Sarin. American Journal of Psychiatry and Neuroscience. https://doi.org/10.11648/j.ajpn.s.2017050601.25
409. Pfeffer, G., Chouinard, G., & Margolese, H. C. (2005). Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200505000-00011
410. Pinto, J. M., Babu, K. M., & Jenny, C. (2013). Cocaine-Induced Dystonic Reaction. Pediatric Emergency Care. https://doi.org/10.1097/pec.0b013e3182a3204d
411. Piróg-Balcerzak, A., Habrat, B., & Mierzejewski, P. (2015). Misuse and abuse of quetiapine. Psychiatria Polska. https://doi.org/10.12740/pp/32923
412. Pombo, R., Johnson, E., Gamboa, A., & Omalu, B. (2017). Autopsy-proven Mirtazapine Withdrawal-induced Mania/Hypomania Associated with Sudden Death. Journal of Pharmacology and Pharmacotherapeutics. https://doi.org/10.4103/jpp.jpp_162_16
413. Pomerantz, J. M. (2008). Early Antidepressant Treatment Is Effective for Post-Stroke Depression.
414. Pongiya, U. D., & Rao, Y. R. (2014). EFFICACY OF HYPERICUM HOOKERIANUM IN REVERSING THE SYMPTOMS OF HALOPERIDOL INDUCED TARDIVE DYSKENESIA, CATATONIA AND CATALEPSY IN SWISS ALBINO MICE - BEHAVIOURAL ANALYSIS REPORT.
415. Pontius, A. A. (1993). NEUROPSYCHIATRIC UPDATE OF THE CRIME "PROFILE" AND "SIGNATURE" IN SINGLE OR SERIAL HOMICIDES: RULE OUT LIMBIC PSYCHOTIC TRIGGER REACTION. Psychological Reports. https://doi.org/10.2466/pr0.1993.73.3.875
416. Pontius, A. A. (1993). Neuropsychiatric Update of the Crime “Profile” and “Signature” in Single or Serial Homicides: Rule out Limbic Psychotic Trigger Reaction<sup>1</sup>. Psychological Reports. https://doi.org/10.1177/00332941930733pt125
417. Popescu, D., Popescu, G., Lupu, G., Panus, V., Neagu-Sadoveanu, S., & Buda, O. (2010). Drugs effects on the central nervous system. Forensic implications. Romanian Journal of Legal Medicine. https://doi.org/10.4323/rjlm.2010.231
418. Potvin, O., Hudon, C., Grenier, S., & Préville, M. (2010). Non-essential symptoms of depression and cognitive impairment no dementia (CIND) in community-dwelling elders without dysphoria or anhedonia. International Psychogeriatrics. https://doi.org/10.1017/s1041610210001419
419. Potvin, S., Stip, É., & Roy, J.-Y. (2004). Schizophrénie et cannabinoïdes. Drogues santé et société. https://doi.org/10.7202/008536ar
420. Prabha, Y. S. (2023). Stress as a Topic of Concern in Gut Health: A Review. UTTAR PRADESH JOURNAL OF ZOOLOGY. https://doi.org/10.56557/upjoz/2023/v44i123527
421. Preiß, M., Rabl, U., Popper, V., Watzal, V., Treiber, M., Ivkic, D., Praschak-Rieder, N., Naderi‐Heiden, A., Fugger, G., Frey, R., Rujescu, D., & Bartova, L. (2023). Case report: Hyperactive delirium after a single dose of zolpidem administered additionally to psychopharmacotherapy including clozapine. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1204009
422. Pytell, J. D., & Rastegar, D. A. (2025). Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0009
423. Queiroz, A. P. D. S., Pedro, M. O. P., Campos, M. W., Torales, J., Ventriglio, A., & Castaldelli-Maia, J. M. (2025). Cognitive Effects of Cannabis Use: A Comprehensive Review Across Domains. Neurology International. https://doi.org/10.3390/neurolint17070107
424. Quera-Salva, M.-A. (2014). Editorial (Thematic Issue: Sleep and Psychiatry). Current Psychiatry Reviews. https://doi.org/10.2174/157340051003140905145825
425. Radhakrishnan, R., Wilkinson, S. T., & Dâ€TMSouza, D. C. (2014). Gone to Pot â€“ A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2014.00054
426. Radovanovi, M. R., Milovanovi, D. R., & Radovanovi, M. S. (2012). Heroin addict with gangrene of the extremities, rhabdomyolysis and severe hyperkalemia Heroinski zavisnik sa gangrenom ekstremiteta, rabdomiolizom i teškom hiperkalemijom.
427. Ramesh, D., Schlosburg, J. E., Wiebelhaus, J. M., & Lichtman, A. H. (2011). Marijuana Dependence: Not Just Smoke and Mirrors. ILAR Journal. https://doi.org/10.1093/ilar.52.3.295
428. Ramsay, D. A. (2014). Ethanol, Trauma, and the Brain. Academic Forensic Pathology. https://doi.org/10.23907/2014.030
429. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
430. RAPOPORT, J. L., & Fiske, A. P. (1998). The New Biology Of Obsessive-Compulsive Disorder: Implications for Evolutionary Psychology. Perspectives in biology and medicine. https://doi.org/10.1353/pbm.1998.0063
431. Rasmussen, K. G., & Ritter, M. J. (2014). Some Considerations of the Tolerability of Ketamine for ECT Anesthesia. Journal of Ect. https://doi.org/10.1097/yct.0000000000000100
432. Rastegar, D. A., & Fingerhood, M. (2015). Cocaine, Methamphetamine, and Other Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0008
433. Rastegar, D. A., & Fingerhood, M. (2015). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0009
434. Rastegar, D. A., & Fingerhood, M. (2015). Marijuana and Other Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0010
435. Reardon, C. L., & Benoy, R. (2023). Addiction (Drugs and Gambling) Disorders in Athletes. Routledge eBooks. https://doi.org/10.4324/9781003099345-12
436. Reddy, S., Elsayem, A., & Talukdar, R. (2005). Palliative Care. CRC Press eBooks. https://doi.org/10.1201/b14119-59
437. Reid, W. H., Balis, G. U., & Sutton, B. (1997). The treatment of psychiatric disorders : revised for DSM-IV.
438. Rigaud, J., Lheureux, P., & Sauder, P. (2006). Prise en charge symptomatique : neurologique, respiratoire, hémodynamique et hépatique des intoxications graves par médicaments et substances illicites. Réanimation. https://doi.org/10.1016/j.reaurg.2006.08.002
439. Riofrío, I. P. B., Jefe, M., De, D., Mental, S., Miller, H., Mt, S., Psiquiatría, D., Dra, H., Velastegui, G. N. J., medico, Psc, R., Alexandra, C., & Torres, L. (2019). Síndrome Neuroléptico Maligno: A propósito de un caso clínico. https://doi.org/10.36015/cambios.v16.n1.2017.279
440. Riskina, C. N. (2020). HUBUNGAN GANGGUAN PSIKOTIK SKIZOFRENIA PARANOID TERHADAP KEHILANGAN GIGI SEBAGIAN PADA PASIEN DI RUMAH SAKIT JIWA BANDA ACEH. ETD Unsyiah.
441. Ritz, L., Pitel, A., Vabret, F., Eustache, F., & Beaunieux, H. (2012). Alcoolodépendance : atteintes neuropsychologiques et diagnostics différentiels. Revue de neuropsychologie. https://doi.org/10.1684/nrp.2012.0227
442. Rivera-Olmos, V. M., & Parra-Bernal, M. C. (2016). [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].. PubMed.
443. Rizvi, N., Whitty, M., & Daly, R. J. (2010). Absinthe and suicidality. Irish Journal of Psychological Medicine. https://doi.org/10.1017/s0790966700000914
444. Roberts, A. J., & Koob, G. F. (1997). The neurobiology of addiction: an overview.. PubMed.
445. Rodríguez, F. D., Sánchez, M. L., & Coveñas, R. (2023). Neurotensin and Alcohol Use Disorders: Towards a Pharmacological Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108656
446. Roessner, V., & Rothenberger, A. (2014). Tic Disorders. https://doi.org/10.1007/978-3-7091-1501-5_27
447. Rohleder, C., & Leweke, F. M. (2023). Cannabidiol as a Potential Antipsychotic. Cambridge University Press eBooks. https://doi.org/10.1017/9781108943246.021
448. Rollin‐Sillaire, A., Delbeuck, X., Pollet, M., Mackowiak, M., Lenfant, P., Noël, M., Façon, T., Leleu, X., Pasquier, F., & Rhun, É. L. (2013). Memory loss during lenalidomide treatment: a report on two cases. BMC Pharmacology and Toxicology. https://doi.org/10.1186/2050-6511-14-41
449. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
450. Roncero, C., Daigre, C., Barral, C., Ros-Cucurull, E., Grau‐López, L., Rodríguez-Cintas, L., Tarifa, N., Casas, M., & Valero, S. (2014). Neuroticism Associated with Cocaine-Induced Psychosis in Cocaine-Dependent Patients: A Cross-Sectional Observational Study. PLoS ONE. https://doi.org/10.1371/journal.pone.0106111
451. Roques, B. (2000). La dangerosité des drogues : mécanismes neurobiologiques des addictions et approches thérapeutiques.. médecine/sciences. https://doi.org/10.4267/10608/1588
452. Roy‐Byrne, P. (2015). Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2015.17.2/proybyrne
453. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
454. Ruiz, C. B., Torralbo, M. B., Garcia, R. R., Llobet, A. H., Fernández, I. A., Nielsen, N. P., Landeo, A. R., Ramírez, M. M., Fuentes, D. G., Soler, M. A., & Cañete, J. (2020). Psicosis dual y cariprazina. Caso clínico. LIBRO COMUNICACIONES. https://doi.org/10.17579/sepd2020p141
455. Rymowicz, R., & Tsuang, T. (2021). Hallucinogen Persisting Perception Disorder Following Recreational Dextromethorphan Use. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0000000000000287
456. Sadikin, A., & Linda, N. (2018). PENYALAHGUNAAN NARKOBA DAN PSIKOTROPIKA DI KALANGAN REMAJA.
457. Safran, A. B., & Sanda, N. (2014). Color synesthesia. Insight into perception, emotion, and consciousness. Current Opinion in Neurology. https://doi.org/10.1097/wco.0000000000000169
458. Sahu, D., Garg, J., & Anand, K. S. (2023). An Interesting Case of Eating Epilepsy. Indian Journal of Medical Specialities. https://doi.org/10.4103/injms.injms_49_23
459. Saifuddin, T. M., Wei, C. W., Ismail, A. F., & Harun, N. A. (2018). Alcohol-Induced Psychotic Disorder with Suicidal Attempt: A Case Report. The Malaysian journal of psychiatry.
460. Salani, D., Albuja, L. D., & Zdanowicz, M. M. (2018). The Explosion of a New Designer Drug, Flakka. Journal of Addictions Nursing. https://doi.org/10.1097/jan.0000000000000252
461. Salkind, A. R. (1997). Coma From Long-term Overingestion of Isoniazid. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1997.00440420156017
462. Salkind, A. R., & Hewitt, C. C. (1997). Coma from long-term overingestion of isoniazid.. PubMed.
463. Santillan, G. H. (2017). Psychopathology of depersonalization and de-realization. What is the limit between normal and pathological?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1377
464. Santos, G., Lima, C. A., & Vitória, J. (2016). Alcohol use disorder following traumatic brain injury: Lessons learned from bench to bedside. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1080
465. Sanxhaku, D., Kodra, V., Alikaj, V., Allkoja, B., & Zenelaj, B. (2017). Child obsessive-compulsive disorder presenting with catatonic-like features: Case presentation. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.461
466. Saraiva, R., Gonçalves, A. S. D. S., Sereijo, C., Castanheira, L. N., Cordeiro, C., Côrte‐Real, B., Queirós, T. P., Barandas, R., Coentre, R., & Abreu, M. (2019). A CASE OF NON ALCOHOLIC WERNICKE KORSAKOFF SYNDROME RESULTING FROM MALNUTRITION DUE TO PSYCHOSIS. https://doi.org/10.26226/morressier.5d1a037357558b317a14038c
467. Sardiani, S. (2023). Aplikasi Asuhan Keperawatan Jiwa Pada Tn. A Dengan Gangguan Persepsi Sensori:Halusinasi Pendengaran Diruangan Dolok Sanggul II. https://doi.org/10.31219/osf.io/kyqd2
468. Sarkar, S. (2017). Psychiatric comorbidities, oral health, and comprehensive care. Oral Health and Care. https://doi.org/10.15761/ohc.1000113
469. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
470. Sarris, J., O’Neil, A., Coulson, C., Schweitzer, I., & Berk, M. (2014). Lifestyle medicine for depression. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-107
471. Scarff, J. R. (2016). The Potential for Somnambulism Associated with Gabapentin. The Internet Journal of Psychiatry.
472. Scarpino, M., Bonizzoli, M., Lanzi, C., Lanzo, G., Lazzeri, C., Cianchi, G., Gambassi, F., Lolli, F., & Grippo, A. (2020). Brain death following ingestion of E‐cigarette liquid nicotine refill solution. Brain and Behavior. https://doi.org/10.1002/brb3.1744
473. Scavone, B. M. (2002). Altered Level of Consciousness after Combined Spinal-Epidural Labor Analgesia with Intrathecal Fentanyl and Bupivacaine. Anesthesiology. https://doi.org/10.1097/00000542-200204000-00033
474. Schep, L. J., Slaughter, R. J., Glue, P., & Gee, P. (2020). The clinical toxicology of cannabis.. PubMed.
475. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
476. Schildkrout, B. (2014). Disease #29: Hypoxia (Insufficient Oxygen Supply to the Brain). https://doi.org/10.1002/9781394260447.ch57
477. Schildkrout, B. (2014). Disease #33: Manganese Toxicity. https://doi.org/10.1002/9781394260447.ch61
478. Schildkrout, B. (2014). Disease #34: Mercury Poisoning. https://doi.org/10.1002/9781394260447.ch62
479. Schildkrout, B. (2014). Disease #62: Thallium Poisoning. https://doi.org/10.1002/9781394260447.ch90
480. Schildkrout, B. (2014). Hallucinations. https://doi.org/10.1002/9781394260447.ch8
481. Schildkrout, B. (2014). Mood, Affect, and Emotion. https://doi.org/10.1002/9781394260447.ch4
482. Schneider, U., Paetzold, W., Emrich, H. M., & Oehlschläger, P. (1999). [Angel trumpets: case report of drug-induced psychosis caused by Brugmansia insigniis].. PubMed.
483. Schoedel, K. A., & Harrison, S. J. (2012). Subjective and Physiological Effects of Oromucosal Sprays Containing Cannabinoids (Nabiximols): Potentials and Limitations for Psychosis Research. Current Pharmaceutical Design. https://doi.org/10.2174/138161212802884708
484. Schutte, M., Mathias, B., & Hopf, G. (1988). [Adverse effects of antihistaminics].. PubMed.
485. Schwartzman, R. J. (2006). Common Patterns of Abnormal Sensation. https://doi.org/10.1002/9780470753262.ch8
486. Schweitzer, J. B. (2010). Attention‐Deficit/Hyperactivity Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0096
487. Scuvée‐Moreau, J. (2013). [Neurobiology of addiction].. PubMed.
488. Sejdić, E., Malandraki, G. A., & Coyle, J. L. (2018). Computational Deglutition: Using Signal- and Image-Processing Methods to Understand Swallowing and Associated Disorders [Life Sciences]. IEEE Signal Processing Magazine. https://doi.org/10.1109/msp.2018.2875863
489. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
490. Serageldin, M., Hikmet, W., & Alani, S. (2019). Insomnia is a Prodromal Symptom for Psychosis. Journal of the Bahrain Medical Society. https://doi.org/10.26715/jbms.31_31012019
491. Shaikh, S., & Lakshmi, R. (2014). Delayed awakening after anaesthesia- A challenge for an anaesthesiologist. International Journal of Biomedical and Advance Research. https://doi.org/10.7439/ijbar.v5i8.829
492. Shams, J., Rahmani, B., Asefi, F., & Daneshfar, S. (2010). CATATONIA DEVELOPMENT IN A SCHIZOAFFECTIVE PATIENT FOLLOWING ELECTROCONVULSIVE THERAPY: CASE REPORT.
493. Sharma, I., Kaur, M., Parashar, B., & Kainth, A. (2014). Depression: An Overview. Asian Journal of Research in Pharmaceutical Sciences.
494. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
495. Shen, Y., Chen, S.-J., & Chou, Y.-H. (2006). "Folie à deux" in a Patient with Mood Swings-A Case Report. 慈濟醫學雜誌. https://doi.org/10.6440/tzucmj.200604.0125
496. Shirata, T., Yano, S., Noto, K., Kanno, M., & Suzuki, A. (2023). Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective <scp>COX</scp>‐2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12325
497. Shrestha, N., & Swayamprava, S. (2017). UNDERSTANDING THE FEATURES OF MADATYAYA (ALCOHOLISM). International Journal of Ayurveda and Pharma Research.
498. Shubina, S. N., & Bubenchik, M. P. (2025). COMPULSIVE OVEREATING AS A COMORBID DISEASE WITH OTHER MENTAL DISORDERS (WITH A CASE DESCRIPTION). Military Medicine. https://doi.org/10.51922/2074-5044.2025.1.130
499. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
500. Simbolon, N. Y., Sitorus, T. R., Meliala, T. L., & Waruwu, P. (2020). TINJAUAN KRIMINOLOGI TERHADAP ANAK YANG MELAKUKAN TINDAK PIDANA PENYALAHGUNAAN NARKOTIKA. JURNAL ILMIAH SIMANTEK.
501. Singh, G., & Kaur, P. (2017). ANTIPSCYHOTIC INDIAN HERBAL FORMULATIONS: AN OVERVIEW. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2017.4.1.6
502. Singh, R. K., Chauhan, V. S., Panda, S. P., Prakash, J., & Chatterjee, K. (2023). Preeclamptic psychosis. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_246_23
503. Skolnick, P., & Crystal, R. (2019). Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose. Journal of Neural Transmission. https://doi.org/10.1007/s00702-019-02132-7
504. Skosnik, P. D., Sewell, R. A., García‐Sosa, I., Ranganathan, M., & D’Souza, D. C. (2010). Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462010000500005
505. Skosnik, P. D., Sewell, R. A., García‐Sosa, I., Ranganathan, M., D’Souza, D. C., & Ribicoff, A. (2010). Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia Efeitos comportamentais, cognitivos e psicofisiológicos de canabinoids: relevância para a psicose e esquizofrenia.
506. Snyder, S. H. (2019). CNS Stimulants And Hallucinogens. CRC Press eBooks. https://doi.org/10.1201/9780429260629-8
507. Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological Disorders in Medical Use of Cannabis: An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170413105421
508. Sommer, I. E., & Arango, C. (2017). Moving interventions from after to before diagnosis. World Psychiatry. https://doi.org/10.1002/wps.20454
509. Sousa, C. D. (2007). Oral Communication 4, Monday Sept. 24th 5.00 pm-6.00 pm; Room: Lecture Hall 1: Attention, emotion and Behavior--Part 2. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agm116
510. Soysal, P., & Işık, A. T. (2014). Hypoactive Delirium Caused by Pulmonary Embolus in an Elderly Adult. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12720
511. Spada, M. M., Caselli, G., & Wells, A. (2012). A Triphasic Metacognitive Formulation of Problem Drinking. Clinical Psychology & Psychotherapy. https://doi.org/10.1002/cpp.1791
512. Spencer, J. (1998). Back to Jellinek. Australasian Psychiatry. https://doi.org/10.3109/10398569809084872
513. Sriramoju, M., Keerthi, V. P., Alumdri, D. B., & Akula, S. (2014). Evaluation of antidepressant activity of ethanolic and aqueous extract of Solanum tuberosum peel. Journal of Comprehensive Pharmacy. https://doi.org/10.37483/jcp.2014.1503
514. Sternbach, H., & State, R. C. (1997). Antibiotics: Neuropsychiatric Effects and Psychotropic Interactions. Harvard Review of Psychiatry. https://doi.org/10.3109/10673229709000304
515. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
516. Sulkowski, A. J. (1980). Marihuana "High": A Model of Senile Dementia?. Perspectives in biology and medicine. https://doi.org/10.1353/pbm.1980.0066
517. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2010-726
518. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201008341-00020
519. Swatko, T., Blicharz, M., Czubala, M., Bartosik-Zielińska, D., Blicharz, A., & Bartosik, M. (2023). Effects of creatine supplementation on brain in the healthy population. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2023.13.04.017
520. Swayamprava, S., Giri, H. C., Ojha, S. K., & Niranjan (2024). Understanding of Alcohol use disorder in Ayurveda. International Journal For Multidisciplinary Research. https://doi.org/10.36948/ijfmr.2024.v06i05.27493
521. Sweet, G., Kim, S., Martin, S. A., Washington, N. B., & Brahm, N. C. (2017). Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians. Mental Health Clinician. https://doi.org/10.9740/mhc.2017.07.156
522. Szaffarczyk, S., Lapierre, P., Danel, T., Cottencin, O., & Pins, D. (2015). Étude du sentiment de familiarité dans l’alcoolo-dépendance : une hyperfamiliarité aux visages. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2015.09.199
523. Tadín, A. (2005). [Substance abuse and the emergency department: a current problem]..
524. Tagaya, H., Murayama, N., & Hakamata, Y. (2012). [Definitions and clinical classifications of sleep disorders].. PubMed.
525. Takács, R., Milan, F., Ungvári, G. S., Faludi, G., & Gazdag, G. (2016). Catatonia in disulfiram intoxication - a case report and a brief overview of the literature.. PubMed.
526. Talabaki, H., Soltani, M., Abbasi, A., Sharifi, V., Salehi, N., & Zakariaei, Z. (2024). Neuropsychiatric manifestations due to anticholinergic agents and anabolic steroids ingestion: A case series and literature review. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12460
527. Tan, S. N., & Lim, E. C. (2020). Intractable Restless Legs Syndrome – Look for Other Causes. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.18177
528. Tanıdır, C., Adaletli, H., Özbek, F., Güneş, H., & Üneri, Ö. Ş. (2015). Ergen yaş grubunda katatoni ve ayırıcı tanısı: Bir olgu sunumu. Dusunen Adam The Journal of Psychiatry and Neurological Sciences. https://doi.org/10.5350/dajpn2015280312
529. Tariq, F. (2012). Premature Ejaculation Re-Visited: Definition and Contemporary Management Approaches. InTech eBooks. https://doi.org/10.5772/25670
530. Tassinari, C. A., Ambrosetto, G., Peraita-Adrado, M. R., & Gastaut, H. (1999). The Neuropsychiatric Syndrome of Δ9-Tetrahydrocannabinol and Cannabis Intoxication in Naive Subjects. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-710-9_64
531. Taylor, M. E., & Whitney, J. (2021). Impaired Cognition and Falls. Cambridge University Press eBooks. https://doi.org/10.1017/9781108594455.009
532. Taylor, S. M., & Beckmann, D. (2021). An adolescent with new-onset inattention. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0028
533. Thiel, H.-J., Bayer, A., Zrenner, E., Ried, S., & Schmidt, D. (1991). Early detection of anticonvulsant drug toxicity by colour vision tests. Noninvasive Assessment of the Visual System. https://doi.org/10.1364/navs.1991.md10
534. Thomas, H. (1993). Psychiatric Symptoms in Cannabis Users. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.163.2.141
535. Tiglao, S. M., Meisenheimer, E. S., & Oh, R. (2021). Alcohol Withdrawal Syndrome: Outpatient Management.. American family physician.
536. Tiscione, N. B., & Rohrig, T. P. (2021). 1,1-Difluoroethane Forensic Aspects for the Toxicologist and Pathologist. Journal of Analytical Toxicology. https://doi.org/10.1093/jat/bkab054
537. Todder, D., & Baune, B. T. (2007). Recurrence of suicidal ideation due to treatment with antidepressants in anxiety disorder: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/1752-1947-1-166
538. Toom, K., Braschinsky, M., Obermann, M., & Katsarava, Z. (2020). Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. https://doi.org/10.1177/0333102420942238
539. Torpy, J. M. (2008). Delirium. JAMA. https://doi.org/10.1001/jama.300.24.2936
540. Torre, R. D. L., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., & Camı́, J. (2004). Human Pharmacology of MDMA. Therapeutic Drug Monitoring. https://doi.org/10.1097/00007691-200404000-00009
541. Torrez, R. D. A., Mercado, A. N. F., Vargas, K. P. C., & Luza, P. L. (2012). Necrosis del cuerpo calloso: Síndrome de Marchiafava - Bignami. DOAJ (DOAJ: Directory of Open Access Journals).
542. Tran, A. T., Rison, R. A., & Beydoun, S. R. (2016). Disulfiram neuropathy: two case reports. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-016-0865-z
543. Tranel, D., McNutt, A., & Bechara, A. (2012). Smoking Cessation After Brain Damage Does Not Lead to Increased Depression. Cognitive and Behavioral Neurology. https://doi.org/10.1097/wnn.0b013e3182492a9c
544. Trevisan, L., Boutros, N. N., Petrakis, I. L., & Krystal, J. H. (1998). Complications of alcohol withdrawal: pathophysiological insights.. PubMed.
545. Tsai, M.-Y., Tsai, M., Yang, S.-C., Tseng, Y., & Chuang, Y. (2009). Transient Global Amnesia-like Episode Due to Mistaken Intake of Zolpidem. Journal of Patient Safety. https://doi.org/10.1097/pts.0b013e3181990d62
546. Tschoe, C., Johnson, L. L., Giugliano, A., & Sarwal, A. (2020). Serotonin Syndrome with Exposure from Tetrahydrocannabinol: a Case Report to Highlight the Side Effects of Increasing Use of CBD Products (5302). Neurology. https://doi.org/10.1212/wnl.94.15_supplement.5302
547. Tugendhaft, P. (2004). [The follow-up of antiepileptic drugs].. PubMed.
548. Udangiu, L. N., Roventa, C. E., & Teodorescu, D. (2010). Clinical and Therapeutic Management of Acute Stress Disorder. Management in Health. https://doi.org/10.5233/mih.2010.0013
549. Uddin, M. S., Sufian, M. A., Kabir, M. T., Hossain, M. F., Nasrullah, M., Islam, I., Mamun, A. A., Islam, M. T., & Khanum, S. (2017). Amphetamines: Potent Recreational Drug of Abuse. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.1000330
550. Valenti, D. A. (2018). MARIJUANA: IMPAIRMENT TO THE VISUAL SENSORY SYSTEM. Innovation in Aging. https://doi.org/10.1093/geroni/igy031.3587
551. Vanderschuren, L. J. M. J. (2008). Neurobehavioral Mechanisms of Compulsive Drug Seeking. https://doi.org/10.1093/oso/9780195300550.003.0009
552. Vega-García, A., Feria-Romero, I. A., García-Juárez, A., Munguia-Madera, A. C., Montes-Aparicio, A. V., Zequeida-Muñoz, E., Garcia-Albavera, E., & Orozco‐Suárez, S. (2021). Cannabinoids: A New Perspective on Epileptogenesis and Seizure Treatment in Early Life in Basic and Clinical Studies. Frontiers in Behavioral Neuroscience. https://doi.org/10.3389/fnbeh.2020.610484
553. Venkataraman, R., Patodia, S., & Thiriveedhi, R. N. (2023). Thrombocytopenia in the Critically Ill: An Animal with Several Heads. Indian Journal of Critical Care Case Report. https://doi.org/10.5005/jp-journals-11006-0089
554. Vernier, L., Rocha, B., Razzolini, D., Bartz, D., & Vargas, G. (2014). Reports of Complaints with Tinnitus Patients: A Qualitative Study. International Archives of Otorhinolaryngology. https://doi.org/10.1055/s-0034-1389005
555. Verster, J. C., Klerk, S. D., Bervoets, A. C., & Kruisselbrink, L. D. (2013). Can Hangover Immunity be Really Claimed.
556. Volpe, U., Vignapiano, A., Gallo, O., & Fabrazzo, M. (2014). Add-on oral olanzapine worsens hallucinations in schizoaffective disorder. BMJ Case Reports. https://doi.org/10.1136/bcr-2014-205805
557. Wadhwa, R., & Khandare, M. (2014). Stress Management through Yoga. Global Journal of Human-Social Science.
558. Walker, M. C. (2020). Narcolepsy. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0576
559. Walker, M. C., Cockerell, O., & Sander, J. W. (1996). Non-Convulsive Status Epilepticus Presenting as a Psychiatric Condition. Journal of the Royal Society of Medicine. https://doi.org/10.1177/014107689608900209
560. Wang, D., Ren, Y.-M., Guo, Y., Zhang, Z., Sui, H., & Zhang, H. (2024). The effects of baicalin in depression: preclinical evidence construction based on meta-analysis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2024.1425094
561. Ward, M., Macfarlane, J. T., Banks, D., Pilkington, R., & Finch, R. (1981). Reducing risks from intravenous cannulae.. BMJ. https://doi.org/10.1136/bmj.282.6279.1838
562. Weisholtz, D. S., & Dworetzky, B. A. (2014). Epilepsy and Psychosis.
563. Weiss, B., Clarkson, T. W., & Simon, W. (2002). Silent latency periods in methylmercury poisoning and in neurodegenerative disease.. Environmental Health Perspectives. https://doi.org/10.1289/ehp.02110s5851
564. Wells, C., & McCormack, S. (2020). Clozapine Initiation for Schizophrenia: A Review of Clinical Effectiveness and Guidelines [Internet].
565. Wiglusz, M. S., Cubała, W. J., Nowak, P. M., Jakuszkowiak‐Wojten, K., Landowski, J., & Krysta, K. (2013). Sibutramine-associated psychotic symptoms and zolpidem-induced complex behaviours: implications for patient safety.. PubMed.
566. Williams, R. H., & Erickson, T. B. (2000). Evaluating Hallucinogenic or Psychedelic Drug Intoxication in an Emergency Setting. Laboratory Medicine. https://doi.org/10.1309/v3j8-3kw2-bpt1-fu15
567. Winerdal, M., Skordas, K., Lidehäll, A. K., Wilhelmsdotter, C., & Strömbergsson, H. (2024). Delayed drug-induced catatonia in an adolescent girl—clinical implications: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-024-04819-2
568. Winston, A. P., Hardwick, E., & Jaberi, N. (2005). Neuropsychiatric effects of caffeine. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.11.6.432
569. Winter, B. Y. D., Prell, T., Axer, H., Witte, O. D., & Großkreutz, J. (2010). Acute Disturbance of Axonal Excitability after controlled Alcohol Intake. Klinische Neurophysiologie. https://doi.org/10.1055/s-0030-1251021
570. Winters, K. C., & Ingwalson, A. (2022). Internalizing and Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0006
571. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
572. Wiśniewski, M., Anand, J. S., Chodorowski, Z., & Kosińska-Tomczyk, H. (2007). [Tiagabine overdose--report of two cases].. PubMed.
573. Wong, O., Fung, H., & Lam, T. (2010). An Unusual Cause of Delirium in a Psychiatric Patient: Abrupt Clozapine Discontinuation. Hong Kong Journal of Emergency Medicine. https://doi.org/10.1177/102490791001700210
574. Woo, C. H., & Kim, S. (2014). Effectiveness of the Military Mental Health Promotion Program. Journal of Korean Academy of Nursing. https://doi.org/10.4040/jkan.2014.44.6.717
575. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
576. Yani, F. (2015). Kelainan Mental Manik Tipe Skizoafektif. Jurnal Medula.
577. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
578. Yates, S. J., Ahuja, N., Gartside, S. E., & McAllister‐Williams, R. H. (2011). Serotonin syndrome following introduction of venlafaxine following withdrawal of phenelzine: implications for drug washout periods. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125311413497
579. Young, W. B., Packard, R. C., & Katsarava, Z. (2007). Headaches Associated with Head Trauma. https://doi.org/10.1093/oso/9780195326567.003.0016
580. Yu-li, H. (2010). 29 Patients with Drug-induced Mental Disorder. China Practical Medicine.
581. Yunita, A. M., Andrianto, H. W., & Susilawati, S. (2018). Implementasi Forward Chaining untuk Identifikasi Dini Penyakit Akibat Ketergantungan Narkoba Jenis Ganja. ProTekInfo(Pengembangan Riset dan Observasi Teknik Informatika). https://doi.org/10.30656/protekinfo.v5i0.1027
582. Yunita, A. M., Andrianto, H. W., & Susilawati, S. (2018). Implementasi Forward Chaining untuk Identifikasi Dini Penyakit Akibat Ketergantungan Narkoba Jenis Ganja. ProTekInfo(Pengembangan Riset dan Observasi Teknik Informatika). https://doi.org/10.30656/protekinfo.v5i0.1028
583. Zainab, A., Shabbir, D., Waqar, K., & Mehmood, A. (2023). Consumption of Cannabis: A Risk Factor or a Therapeutic Agent for Patients with Schizophrenia. https://doi.org/10.1007/978-981-19-7022-1_15
584. Zammit, S., Arseneault, L., & Murray, R. (2011). Does cannabis use cause schizophrenia? The epidemiological evidence. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511706080.016
585. Zanini, R. S., Almeida, G. M. F. D., Helegda, L. C., & Fernandes, K. C. (2014). DEMENCIA DE WERNICKE KORSAKOFF, USO E ABUSO DE SUBSTANCIAS: REPERCUSSÕES NEUROPSICOLÓGICAS E PSICOMOTORAS.. Fiep Bulletin - online.
586. Zawilska, J. B., Santorek‐Strumiłło, E., & Kuna, P. (2010). [Nighttime eating disorders--clinical symptoms and treatment].. PubMed.
587. Zawilska, J. B., Woldan‐Tambor, A., Płocka, A., Kużajska, K., & Wojcieszak, J. (2012). Narcolepsy: etiology, clinical features, diagnosis and treatment. Postępy Higieny i Medycyny Doświadczalnej. https://doi.org/10.5604/17322693.1015529
588. Zouari, R., Nabli, F., Mohamed, D. B., Saeid, M. Z., & Sassi, S. B. (2023). Toxic encephalopathy after an overdose of cocaine : a case serie. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1403
589. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c
590. Çelik, F. H., Aytekin, R., Yıldırım, H., Baykan, N., & Salt, Ö. (2024). A Case of Forgotten Poisoning in a Patient Presenting with Speech Disorder. Eurasian Journal of Toxicology. https://doi.org/10.51262/ejtox.1442548
591. Özer, Ü., Çeri, V., & Evren, C. (2016). Capgras syndrome after use of synthetic cannabinoids: an adolescent case. Dusunen Adam The Journal of Psychiatry and Neurological Sciences. https://doi.org/10.5350/dajpn2016290410
592. Üstündağ, M. F., Ibiş, E. Ö., Yücel, A., & Özcan, H. (2015). Synthetic Cannabis-Induced Mania. Case Reports in Psychiatry. https://doi.org/10.1155/2015/310930
593. Żukiewicz-Sobczak, W., Zwoliński, J., Chmielewska–Badora, J., Krasowska, D., Piątek, J., Sobczak, P., Wojtyła, A., Fornal, E., Kuczumow, A., & Biliński, P. (2012). Analysis of psychoactive and intoxicating substances in legal highs.. PubMed.